documents incorporated reference portions abbvie inc proxy statement incorporated reference part iii proxy statement filed march part item business separation abbott laboratories abbvie incorporated delaware april january abbvie became independent company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott 's shareholders abbvie 's common stock began trading regularway ticker symbol abbv new york stock exchange january overview abbvie global researchbased biopharmaceutical company abbvie develops markets advanced therapies address world 's complex serious diseases abbvie 's products focused treating conditions chronic autoimmune diseases including rheumatoid arthritis psoriasis crohn 's disease hepatitis c hcv human immunodeficiency virus hiv endometriosis thyroid disease parkinson 's disease complications associated chronic kidney disease cystic fibrosis health conditions low testosterone abbvie also pipeline promising new medicines including compounds indications phase phase development across important medical specialties immunology virologyliver disease oncology renal disease neurological diseases women 's health segments abbvie operates one business segmentpharmaceutical products incorporated herein reference note entitled segment geographic area information notes consolidated financial statements included item financial statements supplementary data sales information related humira included item management 's discussion analysis financial condition results operationsresults operations products abbvie 's portfolio products includes broad line therapies address world 's complex serious diseases humira humira biologic therapy administered subcutaneous injection approved treat following autoimmune diseases united states canada mexico collectively north america european union condition principal markets rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylosing spondylitis north america european union crohn 's disease moderate severe north america european union plaque psoriasis moderate severe north america european union juvenile idiopathic arthritis north america european union ulcerative colitis moderate severe united states european union axial spondyloarthropathy united states european union pediatric crohn 's disease severe united states european union pediatric enthesitisrelated arthritis european union used throughout text report term abbvie refers abbvie inc delaware corporation abbvie inc consolidated subsidiaries context requires humira also approved markets including japan china brazil australia humira introduced market january humira accounted percent abbvie 's total net sales united states composition matter compound patent covering adalimumab sold trademark humira expected expire december equivalent european union patent expected expire majority european union countries april abbvie continues dedicate substantial research development efforts expanding indications humira including fields rheumatology gastroenterology pediatric crohn 's disease pediatric ulcerative colitis dermatology pediatric psoriasis hidradenitis suppurativa ophthalmology uveitis phase trials ongoing preparation regulatory applications uveitis united states european union regulatory applications hidradenitis suppurativa filed united states european union abbvie continues work humira formulation delivery enhancements improve convenience overall patient experience hcv products viekira pak alloral shortcourse interferonfree therapy without ribavirin treatment adult patients genotype chronic hepatitis c hcv including compensated cirrhosis viekira pak approved fda december europe abbvie 's hcv treatment marketed viekirax exviera approved use patients genotype genotype hcv european commission granted marketing authorization treatment january additional virology products abbvie 's additional virology products include kaletra norvir treatment hiv infection synagis prevention respiratory syncytial virus rsv infection high risk infants kaletra kaletra also marketed aluvia emerging markets prescription antihiv medicine contains two protease inhibitors lopinavir ritonavir kaletra used antihiv medications treatment maintains viral suppression people hiv norvir norvir ritonavir protease inhibitor indicated combination antiretroviral agents treatment hiv infection synagis synagis product marketed abbvie outside united states protects atrisk infants severe respiratory disease caused rsv metabolicshormones products metabolic hormone products target number conditions including testosterone deficiency exocrine pancreatic insufficiency hypothyroidism products include androgel androgel testosterone replacement therapy males diagnosed symptomatic low testosterone available two strengths percent percent creon creon pancreatic enzyme therapy exocrine pancreatic insufficiency condition occurs patients cystic fibrosis chronic pancreatitis several conditions synthroid synthroid used treatment hypothyroidism abbvie rights sell androgel creon synthroid united states endocrinology products lupron also marketed lucrin lupron depot product palliative treatment advanced prostate cancer treatment endometriosis central precocious puberty preoperative treatment patients anemia caused uterine fibroids lupron approved daily subcutaneous injection onemonth threemonth fourmonth sixmonth intramuscular injection products abbvie 's products include following duopa duodopa abbvie 's levodopacarbidopa intestinal gel treatment advanced parkinson 's disease marketed duopa united states duodopa outside united states anesthesia products sevoflurane sold trademarks ultane sevorane anesthesia product abbvie sells worldwide human use dyslipidemia products abbvie 's dyslipidemia products tricor trilipix niaspan simcor advicor address range metabolic conditions characterized high cholesterol andor high triglycerides zemplar zemplar product sold worldwide treatment secondary hyperparathyroidism associated stage chronic kidney disease ckd research development activities abbvie numerous compounds clinical development including potential treatments complex lifethreatening diseases abbvie 's ability discover develop new compounds enhanced company 's use integrated discovery development project teams include chemists biologists physicians pharmacologists work compounds team research development process generally begins discovery research focuses identification molecule desired effect given disease preclinical testing identified compound proves successful compound moves clinical development generally includes following phases phase involves first human tests small number healthy volunteers patients assess safety tolerability potential dosing phase tests drug 's efficacy disease relatively small group patients phase tests drug demonstrates favorable results earlier phases significantly larger patient population demonstrate efficacy safety based regulatory criteria clinical trials development phases provide data required prepare submit new drug application nda biological license application bla submission regulatory approval fda similar government agencies outside united states specific requirements eg scope clinical trials obtaining regulatory approval vary across different countries geographic regions research development process discovery new drug launch typically takes years even longer research development new pharmaceutical products significant amount inherent uncertainty guarantee molecule receive regulatory approval required launch new drug indication addition development new products new formulations research development projects also may include phase trials sometimes called post marketing studies projects clinical trials designed conducted collect additional data regarding among parameters benefits risks approved drug abbvie spent approximately billion billion billion research discover develop new products indications processes improve existing products processes expenses consisted primarily salaries related expenses personnel license fees consulting payments contract research clinical drug supply manufacturing costs laboratory equipment facilities clinical trial costs collaboration fees expenses intellectual property protection regulatory exclusivity generally upon approval products may entitled certain kinds exclusivity applicable intellectual property regulatory regimes abbvie seeks patent protection available significant markets andor countries product development united states expiration date patents filed june years filing date given patents relating pharmaceutical products often obtained early development process given amount time needed complete clinical trials development activities required regulatory approval length time product launch patent expiration significantly less years drug price competition patent term restoration act commonly known hatchwaxman act permits patent holder seek patent extension commonly called patent term restoration patents products processes making product regulated federal food drug cosmetic act length patent extension roughly based percent period time filing investigational new drug application compound submission nda compound plus percent time period nda submission regulatory approval extension however exceed five years patent term remaining regulatory approval exceed years pharmaceutical products may entitled forms legal regulatory exclusivity upon approval scope length requirements exclusivities varies united states jurisdictions united states fda approves drug product contains active ingredient previously approved product typically entitled five years nonpatent regulatory exclusivity products may entitled three years exclusivity approval based fda 's reliance new clinical studies essential approval submitted nda applicant nda applicant studies product use children fda may grant pediatric exclusivity extends days longest existing exclusivity patent regulatory related product products either used treat conditions afflict relatively small population reasonable expectation research development costs recovered fda may designate pharmaceutical orphan drug grant seven years market exclusivity applicable laws regulations dictate scope exclusivity product entitled upon approval particular country certain instances regulatory exclusivity may protect product patent protection longer available period time excess patent protection possible estimate product development total period scope exclusivity may become entitled regulatory approval obtained however given length time required complete clinical development pharmaceutical product minimum maximum periods exclusivity might achieved individual case would expected exceed three years respectively estimates consider factors difficulty recreating manufacturing process particular product proprietary knowledge may delay introduction generic follow product expiration applicable patent regulatory exclusivity periods biologics may entitled exclusivity biologics price competition innovation act passed march title vii patient protection affordable care act law provides pathway approval biosimilars following expiration years exclusivity innovator biologic potential additional dayextension term conducting pediatric studies biologics also eligible orphan drug exclusivity discussed law also includes extensive process innovator biologic biosimilar manufacturer litigate patent infringement validity enforceability prior approval biosimilar european union also created pathway approval biosimilars published guidelines approval certain biosimilar products complex nature biologics biosimilar products led greater regulatory scrutiny rigorous requirements approval followon biosimilar products small molecule generic pharmaceutical products european union also reduced effect biosimilars sales innovator biologic compared sales erosion caused generic versions small molecule pharmaceutical products abbvie owns licensed rights substantial number patents patent applications abbvie licenses owns patent portfolio thousands patent families includes united states patent applications andor issued patents may also contain nonunited states counterparts patents applications patents applications including various patents expire period aggregate believed material importance operation abbvie 's business however abbvie believes single patent license trademark related group patents licenses trademarks except related adalimumab sold trademark humira material relation company 's business whole united states composition matter compound patent covering adalimumab expected expire december equivalent european union patent expected expire majority european union countries april addition following patents licenses trademarks significant related lopinavirritonavir sold trademarks kaletra aluvia related ombitasvirparitaprevirritonavir dasabuvir sold trademarks viekira pak viekirax exviera holkira pak related testosterone sold trademark androgel united states composition matter patent covering lopinavir expected expire principal united states noncomposition matter patent covering lopinavirritonavir expected expire united states composition matter patents covering ombitasvir paritaprevir dasabuvir expected expire respectively principal united states non composition matter patent covering androgel percent expected expire including pediatric exclusivity agreements may affect exclusivity discussed item management 's discussion analysis financial condition results operationsresults operations abbvie may rely circumstances trade secrets protect technology however trade secrets difficult protect abbvie seeks protect technology product candidates part confidentiality agreements employees consultants advisors contractors collaborators agreements may breached abbvie may adequate remedies breach addition abbvie 's trade secrets may otherwise become known independently discovered competitors extent abbvie 's employees consultants advisors contractors collaborators use intellectual property owned others work company disputes may arise rights related resulting knowhow inventions marketing sales distribution capabilities abbvie utilizes combination dedicated commercial resources regional commercial resources distributorships market sell distribute products worldwide abbvie directs primary marketing efforts toward securing prescription recommendation brand products physicians key opinion leaders health care providers managed care providers example health maintenance organizations pharmacy benefit managers hospitals state federal government agencies example united states department veterans affairs united states department defense also important customers abbvie also markets directly consumers although united states company 's products must sold pursuant prescription outside united states abbvie focuses marketing efforts key opinion leaders payors physicians country regulatory bodies abbvie also provides patient support programs closely related products abbvie 's products sold countries abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses although significant seasonal aspects abbvie 's business abbvie 's product sales may affected end customer retail buying patterns fluctuations wholesaler inventory levels factors united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly pharmacies patients three wholesale distributors mckesson corporation cardinal health inc amerisourcebergen corporation accounted substantially abbvie 's sales united states individual wholesaler accounted greater percent abbvie 's gross sales united states outside united states sales made either directly customers distributors depending market served wholesalers purchase product abbvie standard terms conditions sale certain products comarketed copromoted companies abbvie single customer customer lost would material adverse effect company 's business material portion abbvie 's business subject renegotiation profits termination contracts election government orders generally filled current basis order backlog material abbvie 's business third party agreements abbvie agreements third parties process development analytical services manufacturing certain products abbvie procures certain products services limited number suppliers cases single supply source example filling packaging humira syringes sold outside united states puerto rico performed single supplier two different facilities abbvie currently believe agreement material abbvie 's business substantially dependent upon abbvie maintains significant inventory humira syringes reduce risk supply disruption syringefilling packaging facility united states approved supply syringes primary markets outside united states puerto rico addition abbvie agreements third parties active pharmaceutical ingredient product manufacturing formulation development services fill finish packaging services transportation distribution logistics services certain products abbvie believe manufacturing related agreements material abbvie 's business substantially dependent individual agreement cases abbvie maintains alternate supply relationships utilize without undue disruption manufacturing processes third party fails perform contractual obligations abbvie also maintains sufficient inventory product minimize impact supply disruption abbvie also party certain collaborations arrangements discussed note acquisitions collaborations arrangements notes consolidated financial statements included item financial statements supplementary data certain agreements abbott discussed item management 's discussion analysis financial condition results operationstransition abbott cost operate independent company sources availability raw materials abbvie purchases ordinary course business raw materials supplies essential operations numerous suppliers around world including united states addition certain medical devices components necessary manufacture products provided unaffiliated third party suppliers abbvie experienced recent significant availability problems supply shortages forecasted sales environmental matters abbvie believes operations comply material respects applicable laws regulations concerning environmental protection regulations federal state environmental laws impose stringent limitations emissions discharges environment various manufacturing operations abbvie 's capital operating expenditures pollution control approximately million million respectively capital operating expenditures pollution control estimated approximately million million respectively abbott identified one many potentially responsible parties investigations andor remediations several locations united states including puerto rico comprehensive environmental response compensation liability act commonly known superfund locations transferred abbvie connection separation distribution abbvie become party investigations remediations abbott also engaged remediation several sites transferred abbvie connection separation distribution cooperation environmental protection agency similar agencies feasible predict certainty final costs related investigations remediation activities abbvie believes costs together expenditures maintain compliance applicable laws regulations concerning environmental protection material adverse effect company 's financial position cash flows results operations competition markets abbvie 's products highly competitive abbvie competes researchbased pharmaceuticals biotechnology companies discover manufacture market sell proprietary pharmaceutical products biologics example humira competes number antitnf products approved number disease states abbvie 's virology products compete protease inhibitors antihiv treatments search technological innovations pharmaceutical products significant aspect competition introduction new products competitors changes medical practices procedures result product obsolescence price also competitive factor addition substitution generic pharmaceutical products branded pharmaceutical products creates competitive pressures abbvie 's products patent protection biosimilars competition abbvie 's biologic products affected approval followon biologics also known biosimilars biologics added major therapeutic options treatment many diseases including therapies unavailable inadequate advent biologics also raised complex regulatory issues significant pharmacoeconomic concerns cost developing producing biologic therapies typically dramatically higher conventional small molecule medications many expensive biologic medications used ongoing treatment chronic diseases rheumatoid arthritis inflammatory bowel disease treatment previously untreatable cancer significant investments biologics infrastructure manufacturing necessary produce biologic products significant investments marketing distribution sales organization activities may limit number biosimilar competitors united states fda regulates biologics federal food drug cosmetic act public health service act implementing regulations enactment federal health care reform legislation march provided pathway approval biosimilars public health service act approval process science behind biosimilars complex approval process science behind generic followon versions small molecule products added complexity due steps needed ensure safety efficacy biosimilars highly similar original biologic humira ultimate approval fda dependent upon many factors including showing biosimilar highly similar original product clinically meaningful differences original product terms safety purity potency vitro characterization types data could ordinarily required application show similarity may include analytical data studies demonstrate chemical similarity animal studies including toxicity studies clinical studies law also requires biosimilar must indication approved original biologic manufacturing facility meets standards necessary assure biosimilar safe pure potent furthermore new law provides biosimilar product deemed interchangeable considered fda substitutable original biologic product without intervention health care provider prescribed original biologic product prove biosimilar product interchangeable applicant must demonstrate product expected produce clinical results original biologic product given patient product administered patient safety risks potential diminished efficacy alternating switching use interchangeable biosimilar biologic product original biologic product greater risk using original biologic product without switching new law beginning interpreted implemented fda result ultimate impact implementation meaning likely subject substantial uncertainty years come european union pathway approval biosimilars existed since products come market date mixed impact market share incumbent products significant variation product competitive products although number competitive biologic branded products approved since humira first introduced gained modest share worldwide market abbvie continue face competitive pressure biologics orally administered products regulationdiscovery clinical development united states securing approval market new pharmaceutical product united states requires substantial effort financial resources takes several years complete applicant must complete preclinical tests obtain fda approval commencing clinical trials clinical trials intended establish safety efficacy pharmaceutical product typically conducted three sequential phases although phases may overlap combined required clinical testing successful results submitted fda form nda bla requesting approval market product one indications fda reviews nda bla determine whether product safe effective intended use whether manufacturing compliant current good manufacturing practices cgmp even nda bla receives approval applicant must comply postapproval requirements example holders approval must report adverse reactions provide updated safety efficacy information comply requirements concerning advertising promotional labeling also quality control manufacturing procedures must continue conform cgmp approval fda periodically inspects manufacturing facilities assess compliance cgmp imposes extensive procedural substantive record keeping requirements addition condition approval fda may require postmarketing testing surveillance assess monitor product 's safety efficacy commercialization postapproval regulatory obligations cost complying obligations could expand future outside united states abbvie subject similar regulations outside united states abbvie must obtain approval clinical trial application product applicable regulatory authorities commence clinical trials marketing product approval requirements process vary time required obtain approval may longer shorter required fda approval example abbvie may submit marketing authorizations european union either centralized decentralized procedure centralized procedure mandatory approval biotechnology products many pharmaceutical products provides single marketing authorization valid european union member states centralized procedure single marketing authorization application submitted european medicines agency agency evaluates application makes recommendation european commission makes final determination whether approve application decentralized procedure provides mutual recognition national approval decisions available products subject centralized procedure japan applications approval new product made pharmaceutical medical devices agency pmda bridging studies demonstrate foreign clinical data applies japanese patients may required completing comprehensive review pmda reports ministry health labour welfare approves denies application regulatory process many emerging markets continues evolve many emerging markets including asia generally require regulatory approval obtained large developed market united states country begin complete regulatory review process countries also require local clinical studies conducted order obtain regulatory approval country requirements governing conduct clinical trials product licensing also vary addition postapproval regulatory obligations adverse event reporting cgmp compliance generally apply may vary country example marketing authorization granted european union periodic safety reports must submitted pharmacovigilance measures must implemented regulationcommercialization distribution manufacturing manufacture marketing sale promotion distribution abbvie 's products subject comprehensive government regulation government regulation various national regional federal state local agencies united states countries addresses among matters inspection controls research laboratory procedures clinical investigations product approvals manufacturing labeling packaging marketing promotion pricing reimbursement sampling distribution quality control postmarketing surveillance record keeping storage disposal practices abbvie 's operations also affected trade regulations many countries limit import raw materials finished products laws regulations seek prevent corruption bribery marketplace including united states foreign corrupt practices act united kingdom bribery act provide guidance corporate interactions government officials require safeguards protection personal data addition abbvie subject laws regulations pertaining health care fraud abuse including state federal antikickback false claims laws united states prescription drug manufacturers abbvie also subject taxes well application product user establishment fees compliance laws regulations costly materially affects abbvie 's business among effects health care regulations substantially increase time difficulty costs incurred obtaining maintaining approval market newly developed existing products abbvie expects compliance regulations continue require significant technical expertise capital investment ensure compliance failure comply delay release new product result regulatory enforcement actions seizure recall product suspension revocation authority necessary product 's production sale civil criminal sanctions including fines penalties addition regulatory initiatives abbvie 's business affected ongoing studies utilization safety efficacy outcomes health care products components regularly conducted industry participants government agencies others studies call question utilization safety efficacy previously marketed products cases studies resulted may future result discontinuance limitations marketing products domestically worldwide may give rise claims damages persons believe injured result use access human health care products continues subject investigation action governmental agencies legislative bodies private organizations united states countries major focus cost containment efforts reduce health care costs also made private sector notably health care payors providers instituted various cost reduction containment measures abbvie expects insurers providers continue attempts reduce cost health care products outside united states many countries control price health care products directly indirectly reimbursement payment pricing coverage limitations compulsory licensing budgetary pressures united states countries may also heighten scope severity pricing pressures abbvie 's products foreseeable future united states specifically us federal laws require pharmaceuticals manufacturers pay certain statutorilyprescribed rebates state medicaid programs prescription drugs reimbursed state medicaid plans efforts states seek additional rebates affect abbvie 's business similarly veterans health care act prerequisite participation medicaid federal health care programs requires manufacturers extend additional discounts pharmaceutical products various federal agencies including united states department veterans affairs department defense public health service entities institutions addition recent legislative changes would require similarly discounted prices offered tricare program beneficiaries veterans health care act also established b drug discount program requires pharmaceuticals manufacturers provide products reduced prices various designated health care entities facilities united states states also generic substitution legislation requiring permitting dispensing pharmacist substitute different manufacturer 's generic version pharmaceutical product one prescribed addition federal government follows diagnosisrelated group drg payment system certain institutional services provided medicare medicaid implemented prospective payment system pps services delivered hospital outpatient nursing home home health settings drg pps entitle health care facility fixed reimbursement based diagnosis andor procedure rather actual costs incurred patient treatment thereby increasing incentive facility limit control expenditures many health care products medicare reimburses part b drugs based average sales price plus certain percentage account physician administration costs recently reduced hospital outpatient setting end stage renal disease treatment covered bundled payment likewise creates incentives providers demand lower pharmaceutical prices medicare enters contracts private plans negotiate prices patientadministered medicine delivered part march congress enacted patient protection affordable care act health care education reconciliation act together affordable care act affordable care act abbvie pays fee related pharmaceuticals sales government programs also abbvie began providing discount percent branded prescription drugs sold patients fall medicare part coverage gap donut hole affordable care act also includes provisions known physician payments sunshine act require manufacturers drugs biologics covered medicare medicaid starting record transfers value physicians teaching hospitals report data beginning centers medicare medicaid services subsequent public disclosure similar reporting requirements also enacted state level united states increasing number countries worldwide either adopted considering similar laws requiring disclosure interactions health care professionals failure report appropriate data may result civil criminal fines andor penalties abbvie expects debate continue government levels worldwide marketing availability method delivery payment health care products services abbvie believes future legislation regulation markets serves could affect access health care products services increase rebates reduce prices rate price increases health care products services change health care delivery systems create new fees obligations pharmaceuticals industry require additional reporting disclosure possible predict extent abbvie health care industry general might affected matters discussed abbvie subject corporate integrity agreement cia entered abbott may requires enhancements abbvie 's compliance program contains reporting obligations including disclosure financial payments doctors abbvie fails comply cia office inspector general united states department health human services may impose monetary penalties exclude abbvie federal health care programs including medicare medicaid european union european union adopted directives legislation governing labeling advertising distribution supply pharmacovigilance marketing pharmaceutical products legislation provides mandatory standards throughout european union permits member states supplement standards additional regulations european governments also regulate pharmaceutical product prices control national health care systems fund large part cost products consumers result patients unlikely use pharmaceutical product reimbursed government many european countries government either regulates pricing new product launch subsequent launch direct price controls reference pricing recent years many countries also imposed new additional cost containment measures pharmaceutical products differences national pricing regimes create price differentials within european union lead significant parallel trade pharmaceutical products governments also promote generic substitution mandating permitting pharmacist substitute different manufacturer 's generic version pharmaceutical product one prescribed permitting mandating health care professionals prescribe generic versions certain circumstances addition governments use reimbursement lists limit pharmaceutical products eligible reimbursement national health care systems japan japan national health insurance system maintains drug price list specifying pharmaceutical products eligible reimbursement ministry health labour welfare sets prices products list government generally introduces price cut rounds every year also mandates price decreases specific products new products judged innovative useful indicated pediatric use target orphan small population diseases however may eligible pricing premium government also promoted use generics available emerging markets many emerging markets take steps reduce pharmaceutical product prices cases direct price controls others promotion generic alternatives branded pharmaceuticals since abbvie markets products worldwide certain products local nature variations product lines must also meet local regulatory requirements certain additional risks inherent conducting business outside united states including price currency exchange controls changes currency exchange rates limitations participation local enterprises expropriation nationalization governmental action employees abbvie employed approximately persons january outside united states abbvie 's employees represented unions works councils abbvie believes good relations employees internet information copies abbvie 's annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act available free charge abbvie 's investor relations website wwwabbvieinvestorcom soon reasonably practicable abbvie electronically files material furnishes securities exchange commission abbvie 's corporate governance guidelines outline directorship qualifications code business conduct charters abbvie 's audit committee compensation committee nominations governance committee public policy committee available abbvie 's investor relations website wwwabbvieinvestorcom item risk factors carefully consider following risks information evaluating abbvie abbvie 's common stock following risks could materially adversely affect abbvie 's results operations financial condition cash flows risk factors generally separated three groups risks related abbvie 's business risks related abbvie 's separation abbott risks related abbvie 's common stock based information currently known abbvie believes following information identifies significant risk factors affecting categories risks however risks uncertainties abbvie faces limited set forth risk factors described may order importance probability occurrence additional risks uncertainties presently known abbvie abbvie currently believes immaterial may also adversely affect business addition past financial performance may reliable indicator future performance historical trends used anticipate results trends future periods following risks uncertainties develops actual events events could material adverse effect abbvie 's business results operations financial condition cash flows case trading price abbvie 's common stock could decline risks related abbvie 's business expiration loss patent protection licenses may adversely affect abbvie 's future revenues operating earnings abbvie relies patent trademark intellectual property protection discovery development manufacturing sale products particular patent protection aggregate important abbvie 's marketing pharmaceutical products united states major markets outside united states patents covering abbvie products normally provide market exclusivity important profitability many abbvie 's products patents certain products expire abbvie could face competition lower priced generic products expiration loss patent protection product typically followed promptly substitutes may significantly reduce sales product short amount time abbvie 's competitive position compromised generics otherwise could material adverse effect abbvie 's business results operations addition proposals emerge time time legislation encourage early rapid approval generic drugs proposals enacted law could increase impact generic competition abbvie 's principal patents trademarks described greater detail item businessintellectual property protection regulatory exclusivity item management 's discussion analysis financial condition results operationsresults operations litigation regarding patents described item legal proceedings united states composition matter patent humira abbvie 's largest selling product worldwide net sales approximately billion expected expire december equivalent european union patent expected expire majority european union countries april humira biologic biologics readily substituted uncertain impact loss patent protection would sales humira abbvie 's major products could lose patent protection earlier expected could adversely affect abbvie 's future revenues operating earnings third parties government authorities may challenge seek invalidate circumvent abbvie 's patents patent applications example manufacturers generic pharmaceutical products file may continue file abbreviated new drug applications fda seeking market generic forms abbvie 's products prior expiration relevant patents owned licensed abbvie asserting patents invalid unenforceable andor infringed although challenges abbvie 's intellectual property come businesses governments may also challenge intellectual property rights example court decisions potential legislation relating patents legislation regarding biosimilars regulatory initiatives may result erosion intellectual property protection addition certain governments outside united states indicated compulsory licenses patents may sought domestic policies basis national emergencies hivaids triggered compulsory licenses could diminish eliminate sales profits jurisdictions negatively affect abbvie 's results operations abbvie normally responds challenges vigorously defending patents including filing patent infringement lawsuits patent litigation challenges abbvie 's patents costly unpredictable may deprive abbvie market exclusivity patented product extent abbvie 's intellectual property successfully challenged circumvented extent intellectual property allow abbvie compete effectively abbvie 's business suffer extent countries enforce abbvie 's intellectual property rights require compulsory licensing abbvie 's intellectual property abbvie 's future revenues operating income reduced third party 's intellectual property may prevent abbvie selling products material adverse effect abbvie 's future profitability financial condition third parties may claim abbvie product infringes upon intellectual property resolving intellectual property infringement claim costly time consuming may require abbvie enter license agreements abbvie guarantee would able obtain license agreements commercially reasonable terms successful claim patent intellectual property infringement could subject abbvie significant damages injunction preventing manufacture sale use affected abbvie product products events could material adverse effect abbvie 's profitability financial condition significant event adversely affects humira revenues could material negative impact abbvie 's results operations cash flows humira accounted approximately percent abbvie 's total net sales significant event adversely affects humira 's revenues could material adverse impact abbvie 's results operations cash flows events could include loss patent protection humira approval biosimilars humira discovery previously unknown side effects impaired efficacy increased competition introduction new effective less expensive treatments discontinuation removal market humira reason abbvie 's research development efforts may succeed developing marketing commercially successful products technologies may cause revenues profitability decline remain competitive abbvie must continue launch new products new indications andor brand extensions existing products launches must generate revenue sufficient cover substantial research development costs replace sales profitable products lost displaced competing products therapies failure would material adverse effect abbvie 's revenue profitability accordingly abbvie commits substantial effort funds resources research development must make ongoing substantial expenditures without assurance efforts commercially successful high rate failure biopharmaceutical industry inherent research development new products failure occur point research development process including significant funds invested products appear promising development may fail reach market numerous reasons including failure demonstrate effectiveness safety concerns superior safety efficacy competing therapies failure achieve positive clinical preclinical outcomes beyond current standards care inability obtain necessary regulatory approvals delays approval new products new indications limited scope approved uses excessive costs manufacture failure obtain maintain intellectual property rights infringement intellectual property rights others decisions research studies made early development process pharmaceutical product candidate affect marketing strategy candidate receives approval detailed studies may demonstrate additional benefits help marketing also consume time resources may delay submitting pharmaceutical product candidate approval abbvie guarantee proper balance speed testing made respect pharmaceutical product candidate decisions area would adversely affect abbvie 's future results operations even abbvie successfully develops markets new products enhancements existing products may quickly rendered obsolete changing clinical preferences changing industry standards competitors ' innovations abbvie 's innovations may accepted quickly marketplace existing clinical practices uncertainty thirdparty reimbursement abbvie state certainty whether products development launched whether able develop license otherwise acquire compounds products whether products commercially successful failure launch successful new products new indications existing products may cause abbvie 's products become obsolete causing abbvie 's revenues operating results suffer portion abbvie 's nearterm pharmaceutical pipeline relies collaborations third parties may adversely affect development sale products abbvie depends alliances pharmaceuticals biotechnology companies portion products nearterm pharmaceutical pipeline example abbvie collaborating biogen idec develop treatment relapsing remitting form multiple sclerosis also collaborating roche holding ag discover develop commercialize nextgeneration bcl inhibitor abt patients relapsedrefractory chronic lymphocytic leukemia failures parties meet contractual regulatory obligations abbvie disruption relationships abbvie third parties could adverse effect abbvie 's pharmaceutical pipeline business addition abbvie 's collaborative relationships research development extend many years may give rise disputes regarding relative rights obligations revenues abbvie collaboration partners including ownership intellectual property associated rights obligations could result loss intellectual property rights protection delay development sale potential pharmaceutical products lead lengthy expensive litigation arbitration biologics carry unique risks uncertainties could negative impact future results operations successful discovery development manufacturing sale biologics long expensive uncertain process unique risks uncertainties biologics example access supply necessary biological materials cell lines may limited governmental regulations restrict access regulate transport use materials addition development manufacturing sale biologics subject regulations often complex extensive regulations applicable pharmaceutical products manufacturing biologics especially large quantities often complex may require use innovative technologies manufacturing also requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures biologics also frequently costly manufacture production inputs derived living animal plant material biologics made synthetically failure successfully discover develop manufacture sell biologicsincluding humira could adversely impact abbvie 's business results operations abbvie 's biologic products may become subject competition biosimilars biologics price competition innovation act passed march title vii patient protection affordable care act law created framework approval biosimilars united states could allow competitors reference data biologic products already approved europe european commission granted marketing authorizations several biosimilars pursuant set general product classspecific guidelines biosimilar approvals issued past years addition companies developing biosimilars countries could compete abbvie 's biologic products competitors able obtain marketing approval biosimilars referencing abbvie 's biologic products abbvie 's products may become subject competition biosimilars attendant competitive pressure consequences expiration successful challenge abbvie 's applicable patent rights could also trigger competition products assuming relevant exclusivity period expired result abbvie could face litigation respect validity andor scope patents relating biologic products new products technological advances abbvie 's competitors may negatively affect abbvie 's results operations abbvie competes researchbased pharmaceuticals biotechnology companies discover manufacture market sell proprietary pharmaceutical products biologics example humira competes number antitnf products approved number disease states abbvie 's virology products compete protease inhibitors antihiv treatments competitors may introduce new products develop technological advances compete abbvie 's products therapeutic areas immunology virologyliver disease renal disease dyslipidemia neuroscience abbvie predict certainty timing impact introduction competitors new products technological advances competing products may safer effective effectively marketed sold lower prices superior performance features abbvie 's products could negatively impact abbvie 's business results operations manufacture many abbvie 's products highly exacting complex process abbvie one suppliers encounters problems manufacturing abbvie 's products abbvie 's business could suffer manufacture many abbvie 's products highly exacting complex process due part strict regulatory requirements problems may arise manufacturing variety reasons including equipment malfunction failure follow specific protocols procedures problems raw materials delays related construction new facilities expansion existing facilities including intended support future demand abbvie 's products changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could inhibit continuous supply manmade natural disasters environmental factors problems arise production batch product batch product may discarded abbvie may experience product shortages incur added expenses could among things lead increased costs lost revenue damage customer relations time expense spent investigating cause depending cause similar losses respect batches products problems discovered product released market recall product liability costs may also incurred abbvie uses number products pharmaceutical biologic manufacturing processes sourced single suppliers interruption supply products could adversely affect abbvie 's business results operations abbvie uses number products pharmaceutical biologic manufacturing processes sourced single suppliers failure single source suppliers fulfill contractual obligations timely manner result regulatory noncompliance physical disruption manufacturing site may impair abbvie 's ability deliver products customers timely competitive basis could adversely affect abbvie 's business results operations finding alternative supplier could take significant amount time involve significant expense due nature products need obtain regulatory approvals abbvie guarantee able reach agreement alternative providers regulatory authorities would approve abbvie 's use alternatives abbvie however carry business interruption insurance provides degree protection case failure singlesource supplier significant safety efficacy issues could arise abbvie 's products could material adverse effect abbvie 's revenues financial condition pharmaceutical products receive regulatory approval based data obtained controlled clinical trials limited duration following regulatory approval products used longer periods time many patients investigators may also conduct additional perhaps extensive studies new safety efficacy issues reported new scientific information becomes available including results postmarketing phase trials governments change standards regarding safety efficacy labeling abbvie may required amend conditions use product example abbvie may voluntarily provide required provide updated information product 's label narrow approved indication either could reduce product 's market acceptance safety efficacy issues abbvie product arise sales product could halted abbvie regulatory authorities safety efficacy issues affecting suppliers ' competitors ' products also may reduce market acceptance abbvie 's products new data abbvie 's products products similar products could negatively impact demand abbvie 's products due real perceived safety issues uncertainty regarding efficacy cases could result product withdrawal furthermore new data information including information product misuse may lead government agencies professional societies practice management groups organizations involved various diseases publish guidelines recommendations related use abbvie 's products use related therapies place restrictions sales guidelines recommendations may lead lower sales abbvie 's products abbvie subject product liability claims lawsuits may adversely affect business results operations ordinary course business abbvie subject product liability claims lawsuits alleging abbvie 's products products companies promotes resulted could result unsafe condition injury patients product liability claims lawsuits safety alerts product recalls regardless ultimate outcome may material adverse effect abbvie 's business reputation ability attract retain customers consequences may also include additional costs decrease market share product question lower income exposure claims product liability losses selfinsured product liability claims could material adverse effect abbvie 's business results operations abbvie subject costcontainment efforts pricing pressures could cause reduction future revenues operating earnings changes terms rebate chargeback programs common pharmaceuticals industry could material adverse effect abbvie 's operations costcontainment efforts governments private organizations described greater detail item businessregulationcommercialization distribution manufacturing extent cost containment efforts offset greater demand increased patient access health care factors abbvie 's future revenues operating earnings reduced united states european union countries abbvie 's business experienced downward pressure product pricing pressure could increase future united states practices managed care groups institutional governmental purchasers united states federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act contribute pricing pressures recently enacted changes health care system united states increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result additional pricing pressures numerous major markets worldwide government plays significant role funding health care services determining pricing reimbursement pharmaceutical products consequently markets abbvie subject government decisionmaking budgetary actions respect products particular many european countries ongoing governmentmandated price reductions many pharmaceutical products abbvie anticipates continuing pricing pressures europe differences countries pricing regulations could lead thirdparty crossborder trading abbvie 's products results reduction future revenues operating earnings rebates related government programs feeforservice medicaid medicaid managed care programs arise laws regulations abbvie predict additional government initiatives contain health care costs factors could lead new modified regulatory requirements include higher incremental rebates discounts rebate discount programs arise contractual agreements private payers various factors including market factors ability private payers control patient access products may provide payers leverage negotiate higher additional rebates discounts could material adverse effect abbvie 's operations abbvie subject numerous governmental regulations costly comply regulations develop compliant products processes abbvie 's products subject rigorous regulation numerous international supranational federal state authorities described item business regulationdiscovery clinical development process obtaining regulatory approvals market pharmaceutical product costly time consuming approvals might granted future products additional indications uses existing products timely basis delays receipt failure obtain approvals future products new indications uses could result delayed realization product revenues reduction revenues substantial additional costs addition abbvie guarantee remain compliant applicable regulatory requirements approval obtained product requirements include among things regulations regarding manufacturing practices product labeling advertising postmarketing reporting including adverse event reports field alerts due manufacturing quality concerns abbvie must incur expense spend time effort ensure compliance complex regulations possible regulatory actions could result substantial modifications abbvie 's business practices operations refunds recalls seizures abbvie 's products total partial shutdown production one abbvie 's suppliers ' facilities abbvie supplier remedies alleged violation inability obtain future approvals withdrawals suspensions current products market events could disrupt abbvie 's business material adverse effect business results operations laws regulations affecting government benefit programs could impose new obligations abbvie require change business practices restrict operations future health care industry subject various federal state international laws regulations pertaining government benefit programs reimbursement rebates price reporting regulation health care fraud abuse united states laws include antikickback false claims laws medicaid rebate statute veterans health care act individual state laws relating pricing sales marketing practices violations laws may punishable criminal andor civil sanctions including instances substantial fines imprisonment exclusion participation federal state health care programs including medicare medicaid veterans administration health programs laws regulations broad scope subject change evolving interpretations could require abbvie incur substantial costs associated compliance alter one sales marketing practices addition violations laws allegations violations could disrupt abbvie 's business result material adverse effect business results operations abbvie could subject increased monetary penalties andor sanctions including exclusion federal health care programs fails comply terms may resolution department justice 's investigation sales marketing activities depakote may abbott settled united states federal state investigations sales marketing activities depakote pleading guilty misdemeanor violation food drug cosmetic act agreeing pay approximately million criminal fines forfeitures approximately million resolve civil claims plea agreement abbott submitted term probation initially set years shortened years upon separation abbott abbvie obligations plea agreement transferred become fully binding abbvie conditions probation include certain reporting requirements maintenance certain compliance measures certifications abbvie 's ceo board directors conditions abbvie violates terms probation may face additional monetary sanctions remedies court deems appropriate october court accepted guilty plea imposed agreedupon sentence addition abbott entered fiveyear cia office inspector general united states department health human services oig effective date cia october obligations cia transferred become fully binding abbvie cia requires enhancements abbvie 's compliance program fulfillment reporting monitoring obligations management certifications resolutions abbvie 's board directors among requirements compliance requirements settlement impose additional costs burdens abbvie including form employee training third party reviews compliance monitoring reporting obligations management attention abbvie fails comply cia oig may impose monetary penalties exclude abbvie federal health care programs including medicare medicaid abbvie abbott may subject third party claims shareholder lawsuits connection settlement abbvie may required indemnify portion abbott 's costs international nature abbvie 's business subjects additional business risks may cause revenue profitability decline abbvie 's business subject risks associated business internationally including emerging markets sales outside united states make approximately percent abbvie 's total net sales risks associated abbvie 's operations outside united states include fluctuations currency exchange rates changes medical reimbursement policies programs multiple legal regulatory requirements subject change could restrict abbvie 's ability manufacture market sell products differing local product preferences product requirements trade protection measures import export licensing requirements difficulty establishing staffing managing operations differing labor regulations potentially negative consequences changes interpretations tax laws political economic instability including sovereign debt issues price currency exchange controls limitations participation local enterprises expropriation nationalization governmental action inflation recession fluctuations interest rates potential deterioration economic position credit quality certain nonus countries including europe latin america potential penalties adverse consequences violations anticorruption antibribery similar laws regulations including united states foreign corrupt practices act united kingdom bribery act events contemplated risks may individually aggregate material adverse effect abbvie 's revenues profitability abbvie may acquire businesses license rights technologies products form alliances dispose assets could cause incur significant expenses could negatively affect profitability abbvie may pursue acquisitions technology licensing arrangements strategic alliances dispose assets part business strategy abbvie may complete transactions timely manner costeffective basis may realize expected benefits abbvie successful making acquisition products technologies acquired may successful may require significantly greater resources investments originally anticipated abbvie may able integrate acquisitions successfully existing business could incur assume significant debt unknown contingent liabilities abbvie could also experience negative effects reported results operations acquisition dispositionrelated charges amortization expenses related intangibles charges impairment longterm assets effects could cause deterioration abbvie 's credit rating result increased borrowing costs interest expense additionally changes abbvie 's structure operations revenues costs efficiency resulting major transactions acquisitions divestitures mergers alliances restructurings strategic initiatives may result greater expected costs may take longer expected complete encounter difficulties including need regulatory approval appropriate abbvie dependent wholesale distributors distribution products united states accordingly results operations could adversely affected encounter financial difficulties three wholesale distributorsamerisourcebergen corporation cardinal health inc mckesson corporationaccounted substantially abbvie 's sales united states one significant wholesale distributors encounters financial difficulties distributor may decrease amount business abbvie abbvie may unable collect amounts distributor owes timely basis could negatively impact abbvie 's business results operations abbvie debt obligations could adversely affect business ability meet obligations amount debt abbvie incurred intends incur could important consequences abbvie investors consequences include among things requiring portion abbvie 's cash flow operations make interest payments debt reducing cash flow available fund capital expenditures corporate purposes grow abbvie 's business extent abbvie incurs additional indebtedness risks could increase addition abbvie 's cash flow operations may sufficient repay outstanding debt becomes due abbvie may able borrow money sell assets otherwise raise funds acceptable terms refinance debt abbvie may need additional financing future meet capital needs make opportunistic acquisitions financing may available favorable terms abbvie may need seek additional financing general corporate purposes example may need increase investment research development activities need funds make acquisitions abbvie may unable obtain desired additional financing terms favorable abbvie loses investment grade credit rating adequate funds available acceptable terms abbvie may unable fund expansion successfully develop enhance products respond competitive pressures could negatively affect abbvie 's business abbvie raises additional funds issuing debt entering credit facilities may subject limitations operations due restrictive covenants failure comply covenants could adversely affect abbvie 's business abbvie depends information technology failure systems could adversely affect abbvie 's business abbvie relies sophisticated information technology systems operate business systems potentially vulnerable malicious intrusion random attack loss data privacy breakdown although abbvie invested protection data information technology also monitors systems ongoing basis assurance efforts prevent breakdowns breaches abbvie 's information technology systems could adversely affect abbvie 's business factors material adverse effect abbvie 's profitability financial condition many factors affect abbvie 's profitability financial condition including changes interpretations laws regulations including changes accounting standards taxation requirements product marketing application standards environmental laws differences fair value measurement assets liabilities actual value particularly pension postemployment benefits stockbased compensation intangibles goodwill contingent liabilities litigation absence recorded amount amount recorded minimum compared actual amount changes rate inflation including cost raw materials commodities supplies interest rates market value abbvie 's equity investments performance investments held employee benefit trusts changes creditworthiness counterparties transact business provide services abbvie employee benefit trusts changes business economic political conditions including war political instability terrorist attacks threat future terrorist activity related military action natural disasters cost availability insurance due foregoing events labor disputes strikes slowdowns forms labor union activity pressure thirdparty interest groups risks related abbvie 's separation abbott abbvie 's historical financial information fiscal year prior periods necessarily representative results would achieved separate publicly traded company may reliable indicator future results historical information abbvie annual report fiscal year ended december periods ending prior december refers abbvie 's business operated integrated abbott abbvie 's historical financial information periods derived consolidated financial statements accounting records abbott accordingly financial information periods necessarily reflect financial condition results operations cash flows abbvie would achieved separate publicly traded company periods presented abbvie achieve future additional information past financial performance abbvie 's business basis presentation financial statements abbvie 's business see item management 's discussion analysis financial condition results operations item financial statements supplementary data abbvie builds information technology infrastructure transitions data systems abbvie could incur substantial additional costs experience temporary business interruptions abbvie installing implementing information technology infrastructure support critical business functions including accounting reporting manufacturing process control customer service inventory control distribution abbvie may incur temporary interruptions business operations transition effectively abbott 's existing transactional operational systems data centers transition services support functions abbvie replaces systems abbvie may successful implementing new systems transitioning data may incur substantially higher costs implementation currently anticipated abbvie 's failure avoid operational interruptions implements new systems replaces abbott 's information technology services failure implement new systems replace abbott 's services successfully could disrupt business adversely affect ability collect receivables customers material adverse effect profitability addition abbvie unable replicate transition certain systems ability comply regulatory requirements could impaired abbott may fail perform various transaction agreements executed part separation abbvie may fail necessary systems services place certain transaction agreements expire connection separation abbvie abbott entered separation distribution agreement various agreements including transition services agreements tax sharing agreement international commercial operations agreements finished goods supply agreements contract manufacturing agreements employee matters agreement special products master agreement information technology agreement transitional trademark license agreement certain agreements provide performance services company benefit period time abbvie 's separation abbott abbvie relies abbott satisfy performance payment obligations agreements abbott unable satisfy obligations agreements including indemnification obligations abbvie could incur operational difficulties losses addition abbvie abbott entered longterm arrangements special products master agreement relating certain product rights ex us transition services agreement abbott provide abbvie back office functions services certain markets outside united states abbvie established sufficient back office infrastructure conduct operations markets arrangements could lead disputes abbott abbvie abbvie 's rights certain intellectual property territorial commercialization rights allocation costs revenues abbvie 's products operations outside united states abbvie place systems services abbvie agreements providers services transaction longterm agreements terminate abbvie may able operate business effectively profitability may decline abbvie process creating engaging third parties provide systems services replace many systems services abbott currently provides abbvie may successful effectively efficiently implementing systems services transitioning data abbott 's systems abbvie 's systems services may also expensive less efficient systems services abbott expected provide transition period abbvie developing implementing back office functions administrative systems personnel processes markets outside united states abbott initially provide functions assurance abbvie able fully implement functions effectively without disrupting business markets potential indemnification liabilities abbott pursuant separation agreement could materially adversely affect abbvie separation agreement abbott provides among things principal corporate transactions required effect separation certain conditions separation provisions governing relationship abbvie abbott respect resulting separation among things separation agreement provides indemnification obligations designed make abbvie financially responsible substantially liabilities except certain tax liabilities may exist relating business activities whether incurred prior abbvie 's separation abbott well obligations abbott assumed abbvie pursuant separation agreement including relating depakote abbvie required indemnify abbott circumstances set forth separation agreement abbvie may subject substantial liabilities risks related abbvie 's common stock abbvie guarantee timing amount payment dividends common stock although abbvie expects pay regular cash dividends timing declaration amount payment future dividends stockholders fall within discretion abbvie 's board directors board 's decisions regarding payment dividends depend many factors abbvie 's financial condition earnings capital requirements debt service obligations industry practice legal requirements regulatory constraints factors board deems relevant information see item market registrant 's common equity related stockholder matters issuer purchases equity securities abbvie 's ability pay dividends depend ongoing ability generate cash operations access capital markets abbvie guarantee continue pay dividend future abbvie stockholder 's percentage ownership abbvie may diluted future future stockholder 's percentage ownership abbvie may diluted equity issuances capital market transactions equity awards abbvie granting abbvie 's directors officers employees acquisitions purposes abbvie 's employees options purchase shares common stock result conversion abbott stock options whole part abbvie stock options abbvie anticipates compensation committee grant additional stock options stockbased awards employees awards dilutive effect abbvie 's earnings per share could adversely affect market price abbvie 's common stock time time abbvie issue additional options stockbased awards employees abbvie 's employee benefits plans addition abbvie 's amended restated certificate incorporation authorizes abbvie issue without approval abbvie 's stockholders one classes series preferred stock designation powers preferences relative participating optional special rights including preferences abbvie 's common stock respecting dividends distributions abbvie 's board directors generally may determine terms one classes series preferred stock could dilute voting power reduce value abbvie 's common stock example abbvie could grant holders preferred stock right elect number abbvie 's directors events happening specified events right veto specified transactions similarly repurchase redemption rights liquidation preferences abbvie could assign holders preferred stock could affect residual value common stock certain provisions abbvie 's amended restated certificate incorporation amended restated bylaws delaware law may prevent delay acquisition abbvie could decrease trading price abbvie 's common stock abbvie 's amended restated certificate incorporation amended restated bylaws contain delaware law contains provisions intended deter coercive takeover practices inadequate takeover bids making practices bids unacceptably expensive bidder encourage prospective acquirors negotiate abbvie 's board directors rather attempt hostile takeover provisions include among others inability abbvie 's stockholders call special meeting division abbvie 's board directors three classes directors class serving staggered threeyear term provision stockholders may remove directors cause ability abbvie 's directors stockholders fill vacancies abbvie 's board directors requirement affirmative vote stockholders holding least percent abbvie 's voting stock required amend certain provisions abbvie 's amended restated certificate incorporation abbvie 's amended restated bylaws relating number term election abbvie 's directors filling board vacancies calling special meetings stockholders director officer indemnification provisions addition section delaware general corporation law provides subject limited exceptions persons acquire affiliated person acquires percent outstanding voting stock delaware corporation shall engage business combination corporation including merger consolidation acquisitions additional shares threeyear period following date person affiliates becomes holder percent corporation 's outstanding voting stock abbvie believes provisions protect stockholders coercive otherwise unfair takeover tactics requiring potential acquirors negotiate abbvie 's board directors providing abbvie 's board directors time assess acquisition proposal provisions intended make company immune takeovers however provisions apply even offer may considered beneficial stockholders could delay prevent acquisition abbvie 's board directors determines best interests abbvie abbvie 's stockholders provisions may also prevent discourage attempts remove replace incumbent directors cautionary statement regarding forwardlooking statements annual report contains certain forward looking statements regarding business strategies market potential future financial performance matters words believe expect anticipate project similar expressions among others generally identify forward looking statements speak date statements made matters discussed forward looking statements subject risks uncertainties factors could cause actual results differ materially projected anticipated implied forward looking statements particular information included item business item risk factors item management 's discussion analysis financial condition results operations contain forward looking statements forward looking statement expectation belief future results events expressed expectation belief based current plans expectations abbvie management expressed good faith believed reasonable basis assurance expectation belief result achieved accomplished factors could cause actual results events differ materially anticipated include matters described item risk factors item management 's discussion analysis financial condition results operations abbvie undertake obligation update forwardlooking statements included annual report reflect events circumstances date hereof unless abbvie required applicable securities law item b unresolved staff comments none item properties abbvie 's corporate offices located north waukegan road north chicago illinois abbvie 's principal manufacturing plants following locations united states outside united states abbott park illinois campoverde di aprilia italy barceloneta puerto rico cork ireland jayuya puerto rico ludwigshafen germany north chicago illinois sligo ireland worcester massachusetts leased property addition abbvie manufacturing facilities united states worldwide abbvie believes facilities suitable provide adequate production capacity united states including puerto rico abbvie one distribution center abbvie also four united states research development facilities located abbott park illinois north chicago illinois redwood city california worcester massachusetts outside united states abbvie 's principal research development facilities located shanghai china ludwigshafen germany except noted principal plants united states listed owned abbvie subsidiaries abbvie remaining manufacturing plants facilities owned leased abbvie subsidiaries abbvie item legal proceedings information pertaining legal proceedings provided note entitled legal proceedings contingencies notes consolidated financial statements included item financial statements supplementary data incorporated reference herein item mine safety disclosures applicable executive officers registrant following table lists abbvie 's executive officers first appointed abbvie corporate officer december except otherwise indicated name age position richard gonzalez chairman board chief executive officer laura j schumacher executive vice president business development external affairs general counsel william j chase executive vice president chief financial officer carlos alban executive vice president commercial operations michael severino md executive vice president research development chief scientific officer timothy j richmond senior vice president human resources azita salekigerhardt phd senior vice president operations thomas hurwich vice president controller first appointed corporate officer june mr gonzalez abbvie 's chairman board chief executive officer served abbott 's executive vice president pharmaceutical products group responsible abbott 's worldwide pharmaceutical business including commercial operations research development manufacturing also served president abbott ventures inc abbott 's medical technology investment arm mr gonzalez joined abbott held various management positions briefly retiring including abbott 's president chief operating officer president chief operating officer abbott 's medical products group senior vice president president abbott 's former hospital products division hospira inc vice president president abbott 's health systems division divisional vice president general manager abbott 's diagnostics operations united states canada ms schumacher abbvie 's executive vice president business development external affairs general counsel served abbott 's executive vice president general counsel corporate secretary senior vice president corporate secretary general counsel ms schumacher also responsible abbott 's licensing acquisitions function office ethics compliance ms schumacher joined abbott currently serves director general dynamics corporation mr chase abbvie 's executive vice president chief financial officer served abbott 's vice president licensing acquisitions vice president treasurer divisional vice president controller abbott international mr chase joined abbott mr alban abbvie 's executive vice president commercial operations served abbott 's senior vice president proprietary pharmaceutical products global commercial operations senior vice president international pharmaceuticals vice president western europe canada vice president european operations mr alban joined abbott dr severino abbvie 's executive vice president research development chief scientific officer dr severino served amgen inc senior vice president global development corporate chief medical officer vice president global development vice president therapeutic area head general medicine inflammation global clinical development joined abbvie mr richmond abbvie 's senior vice president human resources served abbott 's divisional vice president compensation benefits group vice president talent rewards divisional vice president talent acquisition mr richmond joined abbott dr salekigerhardt abbvie 's senior vice president operations served abbott 's vice president pharmaceuticals manufacturing supply divisional vice president quality assurance global pharmaceutical operations dr salekigerhardt joined abbott mr hurwich abbvie 's vice president controller served abbott 's vice president internal audit divisional vice president controller abbott diagnostics division mr hurwich joined abbott executive officers abbvie elected annually board directors officers elected board appointed chairman board officers either elected first meeting board directors held annual stockholder meeting appointed chairman board board meeting officer holds office successor duly elected appointed qualified officer 's death resignation removal family relationships executive officers listed part ii item market registrant 's common equity related stockholder matters issuer purchases equity securities principal market principal market abbvie 's common stock new york stock exchange nyse whenissued trading market abbvie 's common stock began nyse december regular way trading abbvie 's common stock began january prior december public market abbvie 's common stock abbvie 's common stock also listed chicago stock exchange traded various regional electronic exchanges outside united states abbvie 's common stock listed nyse euronext paris six swiss exchange market price per share high low high low first quarter second quarter third quarter fourth quarter stockholders stockholders record abbvie common stock january dividends four quarterly dividends paid common stock first quarter cash dividend per share payable february second third fourth quarter dividends per share payable may august november respectively october abbvie 's board directors declared increase quarterly cash dividend per share per share payable february stockholders record january quarterly dividend per share paid common stock timing declaration amount payment dividends abbvie future within discretion board directors depend upon many factors including abbvie 's financial condition earnings capital requirements operating subsidiaries covenants associated certain abbvie 's debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors moreover abbvie determines pay dividend future assurance continue pay dividends amount dividends abbvie inc illinois high impact business hib located federal foreign trade subzone subzone dividends may eligible subtraction base income illinois income tax purposes questions please contact tax advisor performance graph following graph compares cumulative total returns abbvie sp index nyse arca pharmaceuticals index graph covers period january first day abbvie 's common stock began regularway trading nyse december graph assumes invested stock index january also assumes reinvestment dividends stock price performance following graph necessarily indicative future stock price performance comparison cumulative total return performance graph furnished shall deemed filed sec subject section exchange act shall deemed incorporated reference filings securities act amended issuer purchases equity securities c total number shares units total purchased part maximum number number b average publicly approximate dollar value shares price announced shares units may units paid per share plans yet purchased period purchased unit programs plans programs october october november november december december total shares represent shares deemed surrendered abbvie pay exercise price connection exercise employee stock options october november december ii shares purchased open market benefit participants abbvie employee stock purchase plan october november december shares include shares surrendered abbvie satisfy minimum tax withholding obligations connection vesting restricted stock restricted stock units authorization supersedes previouslydisclosed billion stock repurchase program october abbvie announced board directors authorized purchase billion common stock time time item selected financial data following table sets forth abbvie 's selected financial information derived audited consolidated financial statements years ended december ii audited combined financial statements years ended december historical financial statements periods prior january prepared standalone basis derived abbott 's consolidated financial statements accounting records former researchbased pharmaceutical business abbott part abbvie periods presented accordingly abbvie 's financial statements periods prior january presented combined basis reflect abbvie 's financial position results operations cash flows business operated part abbott prior separation conformity generally accepted accounting principles gaap united states historical financial statements periods prior january also reflected allocation expenses related certain abbott corporate functions including senior management legal human resources finance information technology quality assurance expenses allocated abbvie based direct usage benefit identifiable remainder allocated pro rata basis revenues headcount square footage number transactions measures abbvie considers expense allocation methodology results reasonable however allocations may indicative actual expenses would incurred abbvie operated independent standalone publiclytraded company periods presented accordingly historical financial information presented periods prior january may indicative results operations financial position would achieved abbvie independent standalone publiclytraded company periods shown abbvie 's performance periods subsequent december refer separation abbott laboratories basis historical presentation transition abbott cost operate independent company included item management 's discussion analysis financial condition results operations additional information selected financial information read conjunction financial statements accompanying notes included item financial statements supplementary data item management 's discussion analysis financial condition results operations years ended december millions except per share data statement earnings data net sales net earningsa basic earnings per sharea diluted earnings per sharea cash dividends declared per share b na na na weightedaverage basic shares outstandingc weightedaverage diluted shares outstandingc balance sheet data total assets longterm debt lease obligationsd results years ended december included higher expenses associated operating independent standalone publicly traded company historically derived financial statements increases include impact interest expense debt issued november higher tax rate full year incremental costs operating independent company addition results year ended december include aftertax transaction financingrelated costs totaling billion per share incurred connection terminated proposed combination shire plc shire million aftertax charge related research development collaboration agreement calico life sciences llc calico million aftertax charge result entering global collaboration infinity pharmaceuticals inc infinity refer notes audited consolidated financial statements included item financial statements supplementary data information relating termination proposed combination shire collaborations calico infinity respectively b abbvie declared regular quarterly cash dividends aggregating per share common stock addition cash dividend per share common stock declared preseparation earnings january recorded reduction additional paid capital refer note audited consolidated financial statements included item financial statements supplementary data additional information regarding cash dividends declared c january abbott distributed million shares abbvie common stock periods prior separation weighted average basic diluted shares outstanding based number shares abbvie common stock outstanding distribution date refer note audited consolidated financial statements included item financial statements supplementary data information regarding calculation basic diluted earnings per common share years ended december also includes current portion longterm debt lease obligations item management 's discussion analysis financial condition results operations following discussion analysis financial condition abbvie inc abbvie company results operations three years period ended december commentary read conjunction consolidated financial statements accompanying notes appearing item financial statements supplementary data executive overview company overview abbvie global researchbased biopharmaceutical company abbvie develops markets advanced therapies address world 's complex serious diseases abbvie products used treat chronic autoimmune diseases including rheumatoid arthritis psoriasis crohn 's disease hepatitis c hcv human immunodeficiency virus hiv endometriosis thyroid disease parkinson 's disease complications associated chronic kidney disease ckd cystic fibrosis health conditions low testosterone abbvie also pipeline promising new medicines including compounds indications phase phase development across important medical specialties immunology virologyliver disease oncology renal disease neurological diseases women 's health abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly pharmacies patients outside united states sales made either directly customers distributors depending market served certain products comarketed copromoted companies abbvie approximately employees products sold countries abbvie operates one business segmentpharmaceutical products financial results since becoming independent company abbvie 's strategy focused delivering strong financial results returns shareholders ensuring strong sustainable growth business longer term abbvie grew worldwide net sales percent billion driven primarily continued strength humira doubledigit sales growth key products including creon duodopa synthroid sales growth continued reflect impact loss exclusivity company 's lipid franchise resulted loss million revenue prior year generic competition began november tricor july trilipix september niaspan company 's financial performance included delivering fully diluted earnings per share including aftertax transaction financingrelated costs totaling billion incurred connection terminated proposed combination shire plc shire million aftertax charge related research development collaboration agreement calico life sciences llc calico million aftertax charge result entering global collaboration infinity pharmaceuticals inc infinity refer note information regarding termination company 's proposed combination shire note information regarding company 's collaborations calico infinity abbvie 's financial performance also reflected improvement gross margin primarily due favorable product mix across product portfolio operational efficiencies well increased funding support abbvie 's emerging midand latestage pipeline assets additional humira indications company generated cash flows operations billion net aftertax transaction financingrelated costs incurred connection terminated proposed combination shire strong cash flows enabled company continue enhance pipeline licensing collaboration activities pay cash dividends shareholders billion repurchase approximately million shares million addition board directors declared increase company 's quarterly cash dividend per share per share common stock payable february well authorized new billion stock repurchase program expected executed next several years addition financial results abbvie continued advance pipeline including securing regulatory approval united states abbvie 's interferonfree hcv treatment viekira pak well submitting regulatory application european union subsequently approved january abbvie also continued advance previously submitted regulatory applications united states duopa subsequently approved january completed several latestage clinical trials including zinbryta daclizumab treatment relapsingremitting form multiple sclerosis ms registrational programs expanded use humira hidradenitis suppurativa abbvie also augmented pipeline strategic licensing partnering activities including inlicensing duvelisib dual acting pi kinase inhibitor currently investigation use variety hematological malignancies infinity entering novel collaboration calico discover develop commercialize new therapies patients agerelated diseases strategic objectives abbvie expects sales performance driven continued strong growth humira launch viekira pak sales growth certain key products including creon duodopa partially offset decline several products due generic competition including androgel remainder lipid franchise addition abbvie expects achieve operating margin improvements continuing invest pipeline support opportunities oncology hcv immunology well continued investment key products abbvie expects grow operating cash flows enable company continue augment pipeline concerted focus strategic licensing acquisition partnering activity returning cash shareholders via dividends share repurchases abbvie expects continue drive strong humira sales growth several ways abbvie seeks expand humira patient base applying regulatory approval new indications humira treating conditions uveitis hidradenitis suppurativa abbvie also seek drive humira sales growth expanding market share presence underserved markets abbvie plans continue making investments key emerging markets including brazil china russia another key driver abbvie 's performance viekira pak approved united states european union number countries around world abbvie expects support successful launch viekira united states securing payor positions patient access focusing commercial efforts penetration abbvieexclusive parity accounts company launched viekirax several european countries including germany united kingdom canada continues work various governments around world gain reimbursements approvals abbvie continue investment products historically stable sales levels making adjustments necessary increase value product portfolio abbvie plans achieve objective variety ways depending product circumstances example identifying supply chain efficiencies pursuing additional indications optimizing residual value products reach end exclusivity abbvie believes approach allow company maintain strong operating margin rd efforts continue focus significant portion expenditures compounds immunology virologyliver disease oncology renal disease neurological diseases women 's health abbvie 's scientists work advance pipeline specialty molecules demonstrate strong clinical performance patients economic value patients healthcare systems current rd projects described research development section abbvie also continue augment pipeline concerted focus strategic licensing acquisition partnering activity research development research innovation continues key strategic priority abbvie abbvie 's longterm success depends great extent ability continue discover develop innovative pharmaceutical products acquire collaborate compounds currently development biotechnology pharmaceutical companies abbvie 's pipeline includes compounds indications clinical development individually collaboration license agreements programs approximately phase development registration abbvie expects multiple phase programs transition phase programs rd focused therapeutic areas include immunology virologyliver disease oncology renal disease neurological diseases women 's health among others immunology humira approved treat following autoimmune diseases united states canada mexico collectively north america european union condition principal markets rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylosing spondylitis north america european union crohn 's disease moderate severe north america european union plaque psoriasis moderate severe north america european union juvenile idiopathic arthritis north america european union ulcerative colitis moderate severe united states european union axial spondyloarthropathy united states european union pediatric crohn 's disease severe united states european union pediatric enthesitisrelated arthritis european union abbvie continues dedicate rd efforts expanding indications humira including fields gastroenterology dermatology ophthalmology phase trials ongoing preparation regulatory applications humira uveitis united states european union regulatory application hidradenitis suppurativa filed united states european union abbvie also number nextgeneration programs underway address immunemediated conditions including following abbvie 's studies dual variable domain immunoglobulin dvdig technology represents approach target multiple disease causing antigens single biologic agent continue progress proprietary technology could lead nextgeneration biologic treatments complex conditions cancer rheumatoid arthritis multiple pathways involved disease abt dvd directed il tnf currently phase investigation ra abt dvd targeting il alpha beta studied osteoarthritis ongoing phase program abbvie collaborating biotest ag anticd biologic known tregalizumab compound currently phase b clinical trials rheumatoid arthritis psoriasis filgotinib glpg nextgeneration oral janus kinase jak inhibitor developed galapagos nv galapagos collaboration entered first quarter filgotinib currently phase b development treat rheumatoid arthritis may able address autoimmune diseases january phase study evaluate filgotinib treat crohn 's disease initiated abt abbvie 's jak selective inhibitor currently phase b september abbvie entered global collaboration ablynx nv ablynx develop commercialize antiilr nanobody alx treat inflammatory diseases including rheumatoid arthritis systemic lupus erythematosus alx currently phase development rheumatoid arthritis may abbvie entered global collaboration alvine pharmaceuticals inc alvine develop alv novel oral treatment patients celiac disease alv currently phase b development virologyliver disease december us food drug administration fda approved abbvie 's viekira pak alloral interferonfree treatment without ribavirin rbv treatment patients chronic genotype hcv infection including compensated cirrhosis january abbvie announced european commission granted marketing authorizations alloral shortcourse interferonfree treatment viekirax ombitasvirparitaprevirritonavir tablets exviera dasabuvir tablets treatment approved without rbv patients genotype chronic hcv infection including compensated liver cirrhosis hiv coinfection patients opioid substitution therapy liver transplant recipients additionally viekirax approved use rbv genotype chronic hcv patients abbvie 's hcv combination also phase development japan abbvie submitted regulatory application japan abbvie also currently conducting phase studies nextgeneration hcv program includes abt potent protease inhibitor abt abbvie 's new nsa inhibitor oncology abbvie focused development targeted treatments inhibit tumor growth improve response common cancer therapies abbvie 's laterstage oncology pipeline includes following elotuzumab antislam antibody treatment multiple myeloma collaboration bristolmyers squibb bms phase development began june multiple myeloma abbvie bms announced fda granted elotuzumab breakthrough therapy designation use combination lenalidomide dexamethoasone treatment multiple myeloma patients received one prior therapies two phase studies ongoing results expected veliparib abt parpinhibitor phase study brcamutated breast cancer treated chemotherapy initiated veliparib also phase evaluation treatment variety solid tumors abbvie announced initiation four separate phase clinical trials evaluating safety efficacy veliparib combination chemotherapy patients previously untreated locally advanced metastatic squamous nonsmall cell lung cancer nsclc separate study patients nonsquamous nsclc neoadjuvant therapy added carboplatin prior surgery women earlystage triple negative breast cancer patients human epidermal growth factor receptor negative metastatic locallyadvanced breast cancer containing brca andor brca gene mutations added carboplatin paclitaxel venetoclax abt nextgeneration bcl inhibitor development patients relapsedrefractory chronic lymphocytic leukemia two phase studies chronic lymphocytic leukemia cll initiated collaboration abbvie 's development partner roche holding ag abbvie also completed enrollment single arm study evaluating venetoclax patients relapsedrefractory cll harboring p deletion mutation negative prognostic factor abbvie anticipates results study venetoclax also explored use across number different hematologic cancers including nonhodgkin lymphoma diffuse large bcell lymphoma acute myeloid leukemia molecular targets explored antibodydrug conjugate approaches linking antitarget antibodies potent cytotoxic agents european medicines agency ema fda granted orphan drug designation abbvie 's investigational compound abt antiepidermal growth factor receptor antibody drug conjugate evaluated safety efficacy patients glioblastoma multiforme common aggressive type malignant primary brain tumor abbvie inlicensed duvelisib dual acting pi kinase inhibitor currently investigation use variety hematological malignancies infinity duvelisib also investigation use indolent nonhodgkins lymphoma use cll renal disease abbvie 's renal care pipeline includes atrasentan prevention progression diabetic ckd phase study initiated assess atrasentan added standard care progression kidney disease patients stage ckd type diabetes global registrational study expected completed atrasentan potentially first compound launched treat diabetic nephropathy specifically targeting albuminuria slowing progression ckd abbvie previously investigating abt treatment acute kidney injury associated major cardiac vascular surgeries abbvie completed phase b study based results study decided continue development abt neurological diseases abbvie clinical studies underway multiple compounds target receptors brain help regulate mood memory neurological functions conditions including following abbvie collaborating biogen idec develop zinbryta daclizumab treatment relapsingremitting form ms common form affects nearly percent newly diagnosed ms patients phase study zinbryta daclizumab anticd monoclonal antibody successfully completed abbvie process working biogen idec complete global regulatory applications zinbryta daclizumab expected submitted first half january abbvie announced fda approved duopa levodopacarbidopa intestinal gel treatment parkinson 's disease duopa administered using small portable infusion pump delivers levodopa carbidopa directly small intestine continuous hours via procedurallyplaced tube product sold name duodopa outside united states abbvie completed two phase b studies abt annr modulator alzheimer 's disease cognitive impairment associated schizophrenia based results studies abbvie plan advance molecule either indications women 's health abbvie developing novel oral gonadotropinreleasing hormone gnrh antagonist elagolix collaboration neurocrine biosciences treatment endometriosisrelated pain uterine fibroids phase study endometriosis began mid second phase trial endometriosis initiated positive topline efficacy results initial phase study recently announced additional safety efficacy data expected phase study uterine fibroids initiated november transitioned phase b given numerous sources potential future growth individual project expected material cash flows results operations next five years factors considered included rd expenses projected incurred project next year relative abbvie 's total rd expenses well qualitative factors marketplace perceptions impact new product abbvie 's overall market position delays abbvie 's rd activities expected material impact operations aggregate cost complete numerous pharmaceutical projects currently development expected material total cost complete depend upon abbvie 's ability successfully complete project rate project advances nature extent costsharing arrangements ultimate timing completion given potential significant delays high rate failure inherent research development new pharmaceutical products possible accurately estimate total cost complete projects currently development separation abbott laboratories basis historical presentation abbvie incorporated delaware april january abbvie became independent publiclytraded company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott 's shareholders prior separation historical financial statements prepared standalone basis derived abbott 's consolidated financial statements accounting records former researchbased pharmaceutical business abbott part abbvie periods presented accordingly abbvie 's financial statements periods prior january presented combined basis reflect abbvie 's financial position results operations cash flows business operated part abbott prior separation conformity generally accepted accounting principles gaap united states combined financial statements principally represent historical results operations assets liabilities abbott 's former researchbased pharmaceutical business periods prior january historical combined financial statements also reflected allocation expenses related certain abbott corporate functions including senior management legal human resources finance information technology quality assurance expenses allocated abbvie based direct usage benefit identifiable remainder allocated pro rata basis revenues headcount square footage number transactions measures abbvie considers expense allocation methodology results reasonable however allocations may indicative actual expenses would incurred abbvie operated independent standalone publiclytraded company periods presented accordingly historical financial information presented periods prior january may indicative results operations financial position would achieved abbvie independent standalone publiclytraded company periods shown abbvie 's performance periods subsequent december results operations net sales comparisons presented constant currency rates reflect comparative local currency sales prior year 's foreign exchange rates measure provides information change net sales assuming foreign currency exchange rates changed prior current period abbvie believes nongaap measure change net sales constant currency rates used conjunction gaap measure change net sales actual currency rates may provide complete understanding company 's operations facilitate analysis company 's results operations particularly evaluating performance one period another percent change actual constant currency currency rates rates years ended millions united states international net sales sales growth driven continued strength humira united states internationally well sales growth key products including synthroid creon duodopa sales increased despite loss exclusivity abbvie 's consolidated lipid franchise well unfavorable impact foreign exchange rates generic competition began november tricor july trilipix september niaspan following table details sales key products percent change actual constant currency currency rates rates years ended december millions humira united states international total androgel united states kaletra united states international total synagis international lupron united states international total synthroid united states sevoflurane united states international total creon united states dyslipidemia products united states duodopa international viekira pak united states total constant currency basis global humira sales increased percent percent primarily result market growth across therapeutic categories geographies approval new indications higher market share favorable pricing certain geographies abbvie pursuing several new indications help differentiate humira competing products add sustainability future growth humira androgel sales decreased percent primarily due decline overall us testosterone replacement market company expects trend continue androgel sales impacted rebates implemented second half certain account losses early moderation market growth experienced androgel sales expected impacted generic competition early global sales kaletra declined primarily due lower market share resulting impact increasing competition hiv marketplace sales synagis increased percent primarily due increased product uptake compared respectively synthroid sales increased percent percent respectively due strong brand loyalty market leadership favorable pricing sales sevoflurane relatively flat declined percent continued impacted generic competition sales creon grew percent percent respectively primarily driven market growth higher market share creon maintains market leadership pancreatic enzyme market sales abbvie 's consolidated lipid franchise includes tricor trilipix niaspan simcor advicor declined percent percent due introduction generic versions products us market generic competition began november tricor july trilipix september niaspan sales duodopa abbvie 's therapy advanced parkinson 's disease approved europe international markets increased percent percent duopa 's regulatory submission united states approved fda january abbvie launched hcv regimen viekira pak united states following fda approval middecember sales viekira pak reflect shipment launch quantities market support full commercial launch january european commission granted marketing authorizations abbvie 's hcv regimen viekirax ombitasvirparitaprevirritonavir tablets exviera dasabuvir tablets january abbvie expects hcv regimen significant contributor sales growth gross margin percent change years ended december millions gross margin net sales gross margin reflected favorable impact product mix across product portfolio including humira operational efficiencies price increases lower amortization expense intangible assets partially offset effect unfavorable foreign exchange rates loss exclusivity lipid franchise gross margin also includes royalty income million relating prior periods result settlement licensing arrangement partially offset million impairment charge intangible asset selling general administrative percent change years ended december millions selling general administrative net sales sga expenses included transactionrelated costs totaling billion incurred connection terminated proposed combination shire refer note notes consolidated financial statements included item financial statements supplementary data information regarding termination company 's proposed combination shire excluding shire break fee transactionrelated costs increase sga expenses due primarily increased selling marketing support new products including preparations expected launch viekira pak well spending relating new indications geographic expansion humira increases partially offset impact favorable foreign exchange rates sga expenses include million million million respectively costs associated separation abbvie abbott sga expenses also included million charge due additional expenses related branded prescription drug fee july internal revenue service issued final rules regulations branded prescription drug fee annual nontaxdeductible fee payable federal government affordable care act based allocation company 's market share branded prescription drugs sold certain government programs prior year final rules accelerated expense recognition criteria fee obligation year fee paid year market share used allocate fee determined change required abbvie industry participants recognize additional year expense result additional expense million recognized final rules regulations change amount timing annual fees paid sga expenses included restructuring charges aggregating million principally related restructuring certain commercial operations conjunction loss expected loss exclusivity certain products included litigation charges million related investigation sales marketing activities depakote resolved may research development acquired inprocess research development percent change years ended december millions research development net sales acquired inprocess research development rd expense reflected funding support company 's emerging mid latestage pipeline assets continued pursuit additional humira indications increases partially offset impact favorable foreign exchange rate fluctuations rd expense included regulatory milestone payments million million related company 's collaboration rd expenses also included restructuring charges million million acquired inprocess research development iprd expense principally included charge million result entering global collaboration infinity develop commercialize duvelisib treatment patients cancer refer note acquisitions collaborations arrangements notes consolidated financial statements included item financial statements supplementary data additional information related company 's collaborations arrangements iprd expense principally included charge million result entering global license agreement ablynx develop commercialize alx charge million result entering global collaboration alvine develop alv charge million result entering global collaboration galapagos cystic fibrosis therapies charges totaling million result entering several arrangements iprd expense included charge million acquisition abt charge million result entering global collaboration develop commercialize oral nextgeneration jak inhibitor charge million result entering twoyear collaboration agreement research develop commercialize three compounds antibodydrug conjugate approaches expense expense consisted million charge related rd collaboration agreement calico discover develop commercialize new therapies patients agerelated diseases interest expense net interest expense net million million million comprised primarily interest expense outstanding debt november abbvie issued billion longterm debt maturities ranging three years entered interest rate swaps various financial institutions converted billion fixed rate interest rate debt floating interest rate debt commercial paper outstanding december million million billion respectively interest expense net also included million financing related fees incurred connection terminated proposed combination shire bridge facility fees related separation abbott income net income net includes income resolution certain contractual agreements fair value adjustments contingent consideration impairments equity securities income net primarily consisted income million resolution contractual agreement income tax expense effective income tax rate percent percent percent effective tax rate fluctuates year year due allocation company 's taxable earnings among jurisdictions well certain discrete factors events year including acquisitions collaborations increase effective income tax rate principally driven state valuation allowances million additional expenses million related branded prescription drug fee nondeductible increase effective tax rate principally due income tax expense related certain earnings outside united states expected indefinitely reinvested well absence million tax benefits recorded result favorable resolution various tax positions pertaining prior year transition abbott cost operate independent company abbvie continue incur additional ongoing operating expenses operate independent company including cost various corporate headquarters functions incremental information technologyrelated costs incremental costs operate standalone back office infrastructure outside united states abbvie 's transition services agreements abbott united states cover certain corporate support services abbvie historically received abbott services include information technology accounts payable payroll financial functions well engineering support various facilities quality assurance support administrative services terms services agreements vary activity agreements facilitate separation allowing abbvie operate independently prior establishing standalone back office functions across organization date separation abbvie sufficient back office infrastructure operate markets outside united states result abbvie entered transition services agreements abbott provide services outside united states including back office services certain countries three years separation back office services include information technology accounts payable payroll receivables collection treasury financial functions well order entry warehousing administrative services transition services agreements allowed abbvie operate international pharmaceuticals business independently prior establishing standalone back office infrastructure countries transition abbott abbvie continue incur nonrecurring expenses expand international infrastructure addition certain international markets date separation december certain marketing authorizations sell abbvie 's products continued held abbott authorizations could transferred applicable regulatory channels practicable estimate costs would incurred periods presented historical financial statements functions described actual costs would incurred abbvie operated standalone company periods would depended various factors including organizational design outsourcing strategic decisions related corporate functions information technology international back office infrastructure refer note entitled background basis presentation notes consolidated financial statements included item financial statements supplementary data description transactions abbvie abbott financial position liquidity capital resources years ended december millions cash flows provided byused operating activities investing activities financing activities cash flows provided operations billion compared billion decrease primarily due aftertax transaction financing related costs billion incurred connection termination proposed combination shire including net foreign exchange losses related settlement undesignated forward contracts used hedge anticipated foreign currency cash outflows exit certain foreign currency positions decrease also due timing us wholesaler collections investment inventory preparation launch abbvie 's interferon free hcv combination united states starting middecember european union january decrease also due increase abbvie 's voluntary contribution main domestic defined benefit pension plan million million abbvie also made voluntary contribution million plan subsequent december cash outflows related collaborations acquisitions arrangements totaled million including million paid infinity related global collaboration develop duvelisib ipi million fund novel rd collaboration calico abbvie accrued additional million payment calico due satisfaction certain conditions rd collaboration subsequently paid cash outflows related collaborations acquisitions arrangements totaled million including million related global collaboration ablynx nv million related global collaboration alvine cash flows investing activities also reflected capital expenditures including purchase small molecule active pharmaceutical ingredient manufacturing facility singapore net sales purchases shortterm investments company issued redeemed commercial paper balance commercial paper outstanding million million december respectively abbvie may issue additional commercial paper retire commercial paper meet liquidity requirements needed cash dividend payments totaled billion billion october board directors declared quarterly cash dividend per share stockholders record close business january payable february timing declaration amount payment dividends within discretion abbvie 's board directors depend upon many factors including abbvie 's financial condition earnings capital requirements operating subsidiaries covenants associated certain abbvie 's debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors february abbvie 's board directors authorized billion common stock repurchase program effective immediately october abbvie 's board directors authorized new billion stock repurchase program effective immediately superseded prior authorization programs company repurchased approximately million shares million open market approximately million shares million open market purchases abbvie shares may made time time management 's discretion program time limit discontinued time abbvie 's remaining share repurchase authorization billion december cash equivalents also impacted net unfavorable exchange rate changes totaling million principally due impact substantial weakening euro translation company 's eurodenominated assets weakening foreign currencies combination increased concentration cash denominated foreign currencies accumulated anticipation terminated proposed combination shire significant portion cash equivalents december considered reinvested indefinitely foreign subsidiaries abbvie expect reinvestment affect liquidity capital resources funds needed operations united states abbvie would required accrue pay us income taxes repatriate funds abbvie believes sufficient sources liquidity support assumption disclosed amount undistributed earnings december reinvested indefinitely substantially abbvie 's trade receivables greece portugal italy spain governmental health systems abbvie continues monitor economic health economy southern europe heightened economic concerns still exist outstanding net governmental receivables countries december follows net receivables one year net receivables past due millions greece portugal italy spain total abbvie monitors economic conditions creditworthiness customers government regulations funding domestically abroad abbvie regularly communicates customers regarding status receivable balances including payment plans obtains positive confirmation validity receivables abbvie establishes allowance accounts receivable probable collected abbvie also monitors potential periodically utilized factoring arrangements mitigate credit risk although receivables included arrangements historically material amount total outstanding receivables currently abbvie believe economic conditions southern europe material impact company 's liquidity cash flow financial flexibility however government funding become unavailable countries significant adverse changes reimbursement practices occur abbvie may able collect entire balance outstanding december credit facility access capital credit ratings credit facility prior october abbvie party billion unsecured fiveyear revolving credit facility syndicate lenders also supported commercial paper borrowings credit facility enabled company borrow funds floating interest rates october abbvie replaced existing revolving credit facility new billion fiveyear revolving credit facility new revolving credit facility enables company borrow funds unsecured basis variable interest rates contains various covenants december company compliance credit facility covenants commitment fees credit facility material amounts outstanding credit facility december access capital company intends fund shortterm longterm financial obligations mature cash hand future cash flows operations issuing additional debt company 's ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand company 's products solvency customers suppliers deterioration company 's key financial ratios credit ratings material unfavorable changes business conditions current time company believes sufficient financial flexibility issue debt enter financing arrangements attract longterm capital acceptable terms support company 's growth objectives credit ratings july following announcement proposed combination shire moody 's investor service affirmed baa senior unsecured longterm rating prime shortterm rating revised ratings outlook stable positive addition standard poor 's ratings services sp placed corporate credit rating senior unsecured debt rating abbvie creditwatch negative implications october sp affirmed abbvie 's corporate credit rating senior unsecured debt rating removed negative credit watch sp affirmed commercial paper rating place creditwatch changes company 's credit ratings unfavorable changes ratings may adverse impact future financing arrangements however would affect company 's ability draw credit facility would result acceleration scheduled maturities company 's outstanding debt contractual obligations following table summarizes abbvie 's estimated contractual obligations december less one three millions total one year three years five years five years shortterm borrowings research development collaborationsa longterm debt capital lease obligations including current portion interest longterm debtb future minimum noncancelable operating lease commitments purchase obligations otherc longterm liabilitiesd total accounts payable accrued liabilities includes million accrual payment calico due satisfaction certain conditions rd collaboration paid first quarter b includes estimated future interest payments longterm debt securities capital lease obligations interest payments debt calculated future periods using interest rates effect end projected interest payments include related effects interest rate swap agreements certain projected interest payments may differ future based changes floating interest rates factors events projected interest payments pertain obligations agreements outstanding december refer notes discussion regarding company 's debt instruments related interest rate agreements outstanding december annual interest capital lease obligations material c includes company 's significant unconditional purchase obligations commitments exceed company 's projected requirements made normal course business amounts less one year includes voluntary contribution million abbvie made main domestic defined benefit plan subsequent december amounts otherwise exclude pension postemployment benefits related deferred compensation cash outflows timing funding uncertain dependent future movements interest rates investment returns changes laws regulations variables also included amount components longterm liabilities including restructuring refer notes information abbvie enters rd collaboration arrangements third parties may require future milestone payments third parties contingent upon achievement certain development regulatory commercial milestones individually arrangements material one annual reporting period however milestones multiple products covered arrangements would happen reached reporting period aggregate charge expense could material results operations period business perspective payments viewed positive signify product successfully moving development generating likely generate cash flows product sales possible predict reasonable certainty whether milestones achieved timing achievement result potential payments included table contractual obligations refer note consolidated financial statements discussion collaboration arrangements critical accounting policies estimates preparation financial statements accordance us generally accepted accounting principles requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses summary company 's significant accounting policies included note consolidated financial statements certain policies considered critical significantly impact company 's financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain actual results may vary estimates revenue recognition abbvie recognizes revenue persuasive evidence arrangement exists delivery occurred sales price fixed determinable collectability sales price reasonably assured revenue product sales recognized title risk loss passed customer rebates abbvie provides rebates pharmacy benefit management companies state agencies administer federal medicaid program insurance companies administer medicare drug plans wholesalers group purchasing organizations government agencies private entities rebate amounts usually based upon volume purchases using contractual statutory prices product type rebate factors used calculations accrual rebate include identification products sold subject rebate customer government agency price terms apply rebate estimated lag time sale payment rebate using historical trends rebate adjusted current changes abbvie estimates amount rebate paid records liability reduction gross sales abbvie records sale product settlement rebate generally occurs two eight months sale abbvie regularly analyzes historical rebate trends makes adjustments reserves changes trends terms rebate programs rebate chargeback accruals recorded period related sales reflected reduction sales rebates chargebacks totaled billion billion billion respectively percent percent percent respectively gross sales subject rebate onepercentage point increase percentage rebates related annual gross sales would decrease net sales million abbvie considers one percentage point increase reasonably likely increase percentage rebates related gross sales allowances cash discounts returns charged gross sales million million million respectively management analyzes adequacy ending rebate accrual balances quarter united states significant charges gross sales medicaid medicare rebates managed care rebates wholesaler chargebacks medicaid rebates relate federal medicaid program administered state agencies whereby rebates provided participating state local government entities various laws regulations cases supplemental rebates also provided states contractual agreements medicare rebates negotiated managed care organizations manage prescription drug plans covering medicare part drug benefit pharmacy benefit manager rebates arise contractual agreements private health care plans seek reduce costs negotiating discounts pharmaceuticals manufacturers wholesaler chargeback programs wholesaler charges abbvie back difference price paid wholesaler abbvie price paid end customer wholesaler contractual discount agreements negotiated abbvie end customer order evaluate adequacy ending accrual balances type rebate management uses internal external data estimate level inventory distribution channel rebate claims processing lag time rebate external data sources used estimate inventory distribution channel include inventory levels periodically reported wholesalers management estimates processing lag time based periodic sampling claims data estimate rebate percentage net price systems calculations used track sales product customer payer estimate contractual statutory rebate net price abbvie believes systems calculations reliable following table analysis three largest rebate accruals chargeback allowances comprise approximately percent total consolidated rebate provisions charged revenues remaining rebate provisions charged gross sales significant determination operating earnings medicaid managed medicare care wholesaler millions rebates rebates chargebacks balance december provisions payments balance december provisions payments balance december provisions payments balance december historically adjustments prior years ' rebate accruals material net income abbvie employs various techniques verify accuracy claims submitted possible works organizations submitting claims gain insight changes might affect rebate amounts medicaid medicare government agency programs calculation rebate involves interpretations relevant regulations subject challenge change interpretation cash discounts returns cash discounts reliably estimated product returns reliably estimated abbvie 's historical returns low sales return terms sales terms remained relatively unchanged several periods pension postemployment benefits abbvie engages outside actuaries assist determination obligations costs plans direct obligations abbvie valuation funded status net periodic benefit cost plans calculated using actuarial assumptions significant assumptions reviewed annually include discount rate expected longterm rate return plan assets health care cost trend rates significant assumptions used determining calculations disclosed note consolidated financial statements discount rate selected based current market rates highquality fixedincome investments december year abbvie employs yieldcurve approach countries robust bond market exists yield curve developed using highquality bonds discount rate single rate equates discounted cash flows rates utilizing yield curve result yieldcurve approach reflects specific cash flows plans ie duration calculating discount rate countries abbvie reviews various indices corporate bond government bond benchmarks estimate discount rate abbvie 's assumed discount rate significant effect amounts reported defined benefit pension postemployment plans december used calculation net periodic benefit cost basis point change assumed discount rate would following effects abbvie 's calculation net periodic benefit costs projected benefit obligations december basis point millions increase decrease defined benefit plans service cost interest cost projected benefit obligation postemployment plans service cost interest cost projected benefit obligation expected longterm rate return based asset allocation historical performance current view expected future returns abbvie considers inputs longterm focus avoid shortterm market influences current longterm rate return plan assets supported historical performance trust 's actual target asset allocation abbvie 's assumed expected longterm rate return significant effect amounts reported defined benefit pension plans december used calculation net periodic benefit cost december percentage point change assumed expected longterm rate return plan assets would increased decreased net period benefit cost plans million health care cost trend rate selected reviewing historical trends current views projected future health care cost increases current health care cost trend rate supported historical trend experience plan assumed health care cost trend rates significant effect amounts reported health care plans december used calculation net periodic benefit cost percentage point change assumed health care cost trend rates would following effects abbvie 's calculation net periodic benefit costs projected benefit obligation december one percentage point millions increase decrease service cost interest cost projected benefit obligation income taxes abbvie accounts income taxes asset liability method provisions federal state foreign income taxes calculated reported pretax earnings based current tax laws deferred taxes provided using enacted tax rates future tax consequences temporary differences differences financial statement carrying amount assets liabilities respective tax bases tax benefits carryforwards valuation allowance established maintained based currently available information likely portion deferred tax asset realized litigation company subject contingencies legal proceedings claims arise normal course business refer note information loss contingency provisions recorded probable losses management 's best estimate loss best estimate made minimum loss contingency amount within probable range recorded accordingly abbvie often initially unable develop best estimate loss therefore minimum amount could zero recorded information becomes known either minimum loss amount increased resulting additional loss provisions best estimate made also resulting additional loss provisions occasionally best estimate amount changed lower amount events result expectation favorable outcome previously expected significant litigation reserves december valuation goodwill intangible assets abbvie acquired may continue acquire significant intangible assets connection business combinations abbvie records fair value transactions involving purchase sale intangible assets occur frequency companies pharmaceuticals industry valuations usually based discounted cash flow analysis incorporating stage completion discounted cash flow model requires assumptions timing amount future net cash flows risk cost capital terminal values market participants factors significantly affect value intangible asset iprd acquired business combination capitalized indefinitelived intangible asset regulatory approval obtained time accounted definitelived asset amortized estimated useful life iprd acquired transactions business combinations expensed immediately unless deemed alternative future use payments made third parties subsequent regulatory approval capitalized amortized remaining useful life abbvie reviews recoverability definitelived intangible assets whenever events changes circumstances indicate carrying value asset may recoverable goodwill indefinitelived intangible assets relate iprd reviewed impairment annually event could result impairment occurs refer note consolidated financial statements information annually company tests goodwill impairment first assessing qualitative factors determine whether likely fair value less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors could significant effect earnings cash flows overall financial performance whether sustained declines company 's share price company concludes likely fair value reporting unit less carrying amount quantitative impairment test performed abbvie tests indefinitelived intangible assets using quantitative impairment test quantitative impairment tests company uses estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use foreign currency exchange rates selection appropriate discount rate asset groupings assumptions estimates estimates assumptions used consistent company 's business plans market participant 's views company similar companies use alternative estimates assumptions could increase decrease estimated fair value assets potentially result different impacts company 's results operations actual results may differ company 's estimates december goodwill intangible assets net amortization totaled billion billion respectively amortization expense intangible assets million million million respectively impairments goodwill abbvie recorded impairment charge million related certain onmarket product rights japan due increased generic competition charge included cost products sold abbvie recorded impairment charges million certain projects development charges included rd expense impairment charges recorded recent accounting pronouncements may financial accounting standards board issued accounting standards update asu summary amendments create revenue contracts customers topic assets deferred costscontracts customers subtopic amendments asu supersede current revenue recognition requirements core principal new guidance entity recognize revenue depict transfer promised goods services customers amount reflects consideration entity expects entitled exchange goods services guidance effective annual reporting periods beginning december including interim periods within reporting period early application permitted abbvie apply amendments using one following two methods retrospectively prior reporting period presented ii retrospectively cumulative effect initially applying amendments recognized date initial application abbvie currently assessing impact adopting guidance consolidated financial statements item quantitative qualitative disclosures market risk company exposed risk earnings cash flows equity could adversely impacted changes foreign exchange rates interest rates certain derivative instruments used available costeffective basis hedge company 's underlying economic exposures refer note entitled financial instruments fair value measures notes consolidated financial statements included item financial statements supplementary data information regarding company 's financial instruments hedging strategies foreign currency risk abbvie 's primary net foreign currency exposures euro british pound japanese yen various abbvie foreign subsidiaries enter foreign currency forward exchange contracts manage exposures changes foreign exchange rates anticipated transactions denominated currency functional currency local entity contracts designated cash flow hedges variability cash flows due changes foreign currency exchange rates markedtomarket resulting gains losses reflected accumulated comprehensive loss abbvie 's consolidated balance sheets deferred gains losses contracts included cost products sold time products sold third party generally exceeding twelve months december abbvie held billion billion respectively notional amounts contracts abbvie enters foreign currency forward exchange contracts manage exposure foreign currency denominated trade payables receivables intercompany loans contracts designated hedges markedtomarket resulting gains losses reflected net foreign exchange abbvie 's consolidated statements earnings generally offset losses gains foreign currency exposure managed december abbvie held notional amounts billion billion respectively foreign currency forward exchange contracts following table reflects total foreign currency forward contracts outstanding december fair fair weighted carrying weighted carrying average value average value contract exchange receivable contract exchange receivable millions amount rate payable amount rate payable receive primarily us dollars exchange following currencies euro british pound japanese yen currencies na na total company estimates percent appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million december realized appreciation would negatively affect earnings remaining life contacts percent appreciation believed reasonably possible nearterm change foreign currencies gains losses hedging instruments offset losses gains hedged transactions reduce earnings stockholders ' equity volatility relating foreign exchange company estimates percent depreciation abbvie 's significant foreign currency positions us dollar would cause foreign exchange loss cash shortterm investments million december percent depreciation believed reasonably possible nearterm change currencies company 's venezuelan operations continue report us dollar functional currency due hyperinflationary status venezuelan economy currency restrictions enacted venezuela require abbvie obtain approval venezuelan government exchange venezuelan bolivars us dollars require exchange made official exchange rate established government effective february venezuelan government devalued official exchange rate resulted loss million recorded net foreign exchange loss consolidated statement earnings first quarter venezuelan government expanded number exchange mechanisms three rates exchange december cencoex rate official rate sicad rate approximately sicad ii rate approximately february venezuelan government confirmed official exchange rate venezuelan bolivars per us dollar used settlement food medicine purchases company continues use official rate venezuelan bolivars per us dollar report venezuela financial position results operations cash flows since company believes nature abbvie 's business operations qualify official rate permitted law company predict whether devaluations venezuelan currency whether use official rate continue supported evolving facts circumstances circumstances change company concludes would appropriate use different rate devaluation official rate occurs could result significant change abbvie 's results operations december abbvie approximately million net monetary assets denominated venezuelan bolivar converted rate vefusd venezuelan entity net sales million abbvie 's net monetary assets denominated venezuelan bolivar converted rate vefusd december would resulted devaluation loss million interest rate risk interest rate swaps used manage company 's exposure changes interest rates fair value fixedrate debt effect hedges change fixed interest rate variable rate abbvie use derivative instruments interest rate swaps manage exposure changes interest rates investment securities december abbvie interest rate hedge contracts totaling billion company estimates increase interest rates basis points would decrease fair value interest rate swap contracts approximately million december realized fair value reduction would affect earnings remaining life contracts company estimates increase basis points longterm interest rates would decrease fair value longterm debt million december basis point change believed reasonably possible nearterm change interest rates market price sensitive investments abbvie holds equity securities strategic technology acquisitions traded public stock exchanges fair value investments approximately million million december respectively abbvie monitors investments temporary declines market value charges impairment losses income temporary decline value occurs hypothetical percent decrease share prices investments would immaterial decrease fair value december percent decrease believed reasonably possible nearterm change share prices nonpublicly traded equity securities abbvie holds equity securities strategic technology acquisitions traded public stock exchanges carrying value investments approximately million million december respectively abbvie monitors investments temporary declines market value charges impairment losses income temporary decline estimated value occurs item financial statements supplementary data consolidated financial statements consolidated statements earnings consolidated statements comprehensive income consolidated balance sheets consolidated statements equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm report independent registered public accounting firm abbvie inc subsidiaries consolidated statements earnings years ended december millions except per share data net sales cost products sold selling general administrative research development acquired inprocess research development expense total operating costs expenses operating earnings interest expense net net foreign exchange loss income net earnings income tax expense income tax expense net earnings per share data basic earnings per share diluted earnings per share cash dividends declared per common share na weightedaverage basic shares outstanding b weightedaverage diluted shares outstanding b january cash dividend per share common stock declared preseparation earnings recorded reduction additional paidin capital refer note additional information regarding cash dividends declared b january abbott laboratories distributed million shares abbvie common stock periods prior separation weightedaverage basic diluted shares outstanding based number shares abbvie common stock outstanding distribution date refer note information regarding calculation basic diluted earnings per common share years ended december accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated statements comprehensive income years ended december millions net earnings foreign currency translation adjustments net tax benefit expense pension postemployment benefits net tax benefit expense unrealized losses gains marketable equity securities net tax expense benefit hedging activities net tax expense benefit comprehensive loss income comprehensive income accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated balance sheets december millions except share data assets current assets cash equivalents shortterm investments accounts receivables net inventories net income tax receivable deferred income taxes prepaid expenses total current assets investments property equipment net intangible assets net amortization goodwill assets total assets liabilities equity current liabilities shortterm borrowings current portion longterm debt lease obligations accounts payable accrued liabilities total current liabilities longterm liabilities longterm debt lease obligations commitments contingencies stockholders ' equity common stock par value authorized shares issued shares december respectively common stock held treasury cost shares december respectively additional paidincapital retained earnings accumulated comprehensive loss total stockholders ' equity total liabilities equity accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated statements equity accumulated common additional net parent years ended december shares common treasury paidin comprehensive retained company millions outstanding stock stock capital loss earnings investment total balance december net earnings net transactions abbott laboratories assumption accumulated unrealized losses pension post employment benefits net tax benefit comprehensive loss net tax balance december separationrelated adjustments reclassification parent company net investment connection separation issuance common stock separation net earnings comprehensive income net tax dividends declared share repurchases stockbased compensation plans balance december net earnings comprehensive loss net tax dividends declared share repurchases stockbased compensation plans balance december accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated statements cash flows years ended december millions brackets denote cash outflows cash flows operating activities net earnings adjustments reconcile net earnings net cash operating activities depreciation amortization intangible assets stockbased compensation upfront costs related collaborations acquired inprocess research development net changes operating assets liabilities net acquisitions accounts receivables inventories prepaid expenses assets accounts payable liabilities cash flows operating activities cash flows investing activities acquisitions investments net cash acquired acquisitions property equipment purchases investment securities sales maturities investment securities cash flows investing activities cash flows financing activities net change shortterm borrowings dividends paid purchases treasury stock proceeds exercise stock options proceeds issuance longterm debt net transactions abbott laboratories excluding noncash items net cash flows financing activities effect exchange rate changes cash equivalents net decrease increase cash equivalents cash equivalents beginning year cash equivalents end year supplemental information interest paid net portion capitalized income taxes paid cash flows operating activities included impact transaction financingrelated costs incurred connection terminated proposed combination shire refer note additional information accompanying notes integral part consolidated financial statements abbvie inc subsidiaries notes consolidated financial statements note background basis presentation background principal business abbvie inc abbvie company discovery development manufacture sale broad line pharmaceutical products abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses substantially abbvie 's sales united states three wholesalers outside united states products sold primarily customers distributors depending market served abbvie incorporated delaware april january abbvie became independent publiclytraded company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott 's shareholders separation january abbott 's shareholders record close business december received one share abbvie common stock every one share abbott common stock held record date abbvie 's common stock began trading regularway ticker symbol abbv new york stock exchange january year ended separationrelated adjustments totaling billion recorded stockholders ' equity separationrelated adjustments additional paidin capital principally reflected dividends abbvie shareholders declared preseparation earnings first quarter transfer certain pension plan liabilities assets abbott abbvie upon legal split plans addition historical financial statements derived abbott 's records separationrelated adjustments also included adjustment accumulated comprehensive loss reflect appropriate opening balances associated currency translation adjustments related abbvie 's legal entities separation date refer note information regarding separation pension plans connection separation abbvie abbott entered transition services agreements covering certain corporate support back office services abbvie historically received abbott services include information technology accounts payable payroll receivables collection treasury financial functions well order entry warehousing engineering support quality assurance support administrative services agreements facilitate separation allowing abbvie operate independently prior establishing standalone back office functions across organization transition services may provided months option oneyear extension majority transaction service agreements expired without extension december years ended december abbvie incurred million million million respectively separationrelated expenses including legal information technology regulatory fees principally classified selling general administrative expenses sga consolidated statements earnings basis historical presentation certain portion abbvie 's operations legal transfer abbvie 's assets net liabilities occur separation abbvie january due time required transfer marketing authorizations satisfy regulatory requirements certain countries terms separation agreement abbott abbvie responsible business activities conducted abbott behalf subject risks entitled benefits generated operations assets result related assets liabilities results operations reported abbvie 's consolidated financial statements years ended december net sales related operations years ended december totaled approximately million million respectively december assets liabilities consisted primarily accounts receivable million inventories million assets million accounts payable accrued liabilities million december assets liabilities consisted primarily accounts receivable million inventories million assets million accounts payable accrued liabilities million majority operations expected transferred abbvie end prior separation january historical financial statements abbvie prepared standalone basis derived abbott 's consolidated financial statements accounting records former researchbased pharmaceutical business abbott part abbvie periods presented accordingly abbvie 's financial statements periods prior january presented herein combined basis reflect abbvie 's financial position results operations cash flows business operated part abbott prior separation conformity us generally accepted accounting principles gaap historical combined financial statements included allocation certain assets liabilities historically held abbott corporate level specifically identifiable allocable abbvie prior cash equivalents shortterm investments restricted funds held abbott allocated abbvie unless assets held entity transferred abbvie december abbvie 's combined balance sheet reflected direct holdings abbvie legal entities prior november longterm debt shortterm borrowings allocated abbvie none debt recorded abbott directly attributable guaranteed abbvie november abbvie issued billion longterm debt maturities ranging three years billion commercial paper reflected abbvie 's combined balance sheet december abbvie intracompany transactions accounts eliminated prior intercompany transactions abbvie abbott considered effectively settled historical combined financial statements time transactions recorded result total net effect settlement intercompany transactions reflected combined statement cash flows year ended december financing activity combined balance sheet december net parent company investment abbvie december outstanding transactions abbvie abbott reflected combined balance sheet outside net parent company investment abbvie inc december aggregate amount due abbott totaled million million respectively primarily classified accounts receivables net abbvie 's consolidated balance sheets aggregate amount due abbott totaled million million december respectively classified accounts payable accrued liabilities abbvie 's consolidated balance sheets prior separation january abbott provided abbvie certain services included administration treasury payroll employee compensation benefits travel meeting services public investor relations real estate services internal audit telecommunications information technology corporate income tax selected legal services services continue provided abbvie temporary basis separation pursuant certain transition services agreements abbvie 's historical combined financial statements periods prior january reflect allocation expenses related services expenses allocated abbvie based direct usage benefit identifiable remainder allocated pro rata basis revenues headcount square footage number transactions measures abbvie considers expense allocation methodology results reasonable however allocations may indicative actual expenses would incurred abbvie operated independent publiclytraded company periods prior january allocations totaled million year ended december prior separation january abbvie employees participated various benefits stockbased compensation programs maintained abbott portion cost programs included abbvie 's historical combined financial statements see note note description accounting postemployment benefits stockbased compensation respectively note summary significant accounting policies use estimates financial statements prepared accordance us gaap necessarily include amounts based estimates assumptions management actual results could differ amounts significant estimates include amounts sales rebates pension postemployment benefits income taxes litigation valuation intangible assets goodwill financial instruments inventory accounts receivable exposures basis consolidation consolidated financial statements years ended december include accounts abbvie subsidiaries controlling interest maintained controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities abbvie determined primary beneficiary investments companies abbvie significant influence controlling interest accounted using equity method abbvie 's share earnings losses reported income net investments generally accounted using cost method intercompany balances transactions eliminated certain reclassifications made conform prior period consolidated financial statements current period presentation revenue recognition abbvie recognizes revenue persuasive evidence arrangement exists delivery occurred sales price fixed determinable collectability sales price reasonably assured revenue product sales recognized title risk loss passed customer provisions discounts rebates sales incentives customers returns adjustments provided period related sales recorded sales incentives customers material historical data readily available reliable used estimating amount reduction gross sales revenue launch new product improved version existing product shipments excess customer 's normal requirements recorded conditions noted met situations management records returns reserve revenue necessary sales product rights marketable products recorded revenue upon disposition rights research development costs internal research development rd costs expensed incurred clinical trial costs incurred third parties expensed contracted work performed contingent milestone payments due third parties research development collaborations precommercialization milestones milestone payment obligations expensed milestone results achieved payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangible assets net accumulated amortization collaborations arrangements company enters collaborative agreements third parties develop commercialize drug candidates collaborative activities may include joint research development commercialization new products abbvie generally receives certain licensing rights arrangements collaborations often require upfront payments may include additional milestone research development cost sharing royalty profit share payments contingent upon occurrence certain future events linked success asset development commercialization upfront payments associated collaborative arrangements development stage expensed acquired inprocess research development iprd subsequent payments made partner achievement milestones development stage expensed rd milestone achieved milestone payments made partner subsequent regulatory approval capitalized intangible assets amortized cost products sold estimated useful life related asset royalties expensed cost products sold incurred advertising costs associated advertising expensed incurred included sga abbvie 's consolidated statements earnings advertising expenses million million million respectively pension postemployment benefits abbvie records annual expenses relating defined benefit pension postemployment plans based calculations include various actuarial assumptions including discount rates assumed asset rates return compensation increases turnover rates health care cost trend rates abbvie reviews actuarial assumptions annual basis makes modifications assumptions based current rates trends actuarial losses gains amortized remaining service attribution periods employees corridor method accordance rules accounting postemployment benefits differences expected longterm return plan assets actual annual return amortized net period benefit cost fiveyear period prior separation abbvie employees participated certain defined benefit pension postemployment plans sponsored abbott included participants abbott 's businesses plans accounted multiemployer plans abbvie 's historical combined financial statements year ended december result asset liability recorded abbvie historical combined balance sheets recognize funded status plans subsequent separation abbott abbvie 's portion defined benefit pension plans separated abbott defined benefit pension plans using december measurement date result funded status plan reflected abbvie 's consolidated balance sheets december abbvie sole sponsor certain defined benefit pension postemployment plans funded status plans recorded abbvie 's combined balance sheet december consolidated balance sheets december refer note information regarding abbvie 's pension postemployment plans income taxes income taxes accounted asset liability method provisions federal state foreign income taxes calculated reported pretax earnings based current tax laws deferred taxes provided using enacted tax rates future tax consequences temporary differences differences financial statement carrying amount assets liabilities respective tax bases tax benefits carryforwards valuation allowance established maintained based currently available information likely portion deferred tax asset realized abbvie 's financial statements periods prior income tax expense tax balances calculated abbvie separate taxpayer although abbvie 's operations historically included tax returns filed abbott separation abbvie 's income tax expense income tax balances represent abbvie 's federal state foreign income taxes independent company result effective tax rate income tax balances necessarily comparable periods prior separation cash equivalents cash equivalents include time deposits money market funds treasury securities original maturities time purchase three months less investments shortterm investments consist primarily time deposits heldtomaturity debt investments marketable equity securities classified availableforsale recorded fair value unrealized holding gains losses net tax included accumulated comprehensive loss abbvie 's consolidated balance sheets investments equity securities traded public stock exchanges heldtomaturity debt securities recorded cost abbvie reviews carrying value investments quarter determine whether temporary decline fair value exists abbvie considers factors affecting investee factors affecting industry investee operates general equity market trends company considers length time investment 's fair value cost nearterm prospects recovery abbvie determines temporary decline occurred cost basis investment written charge income net availableforsale securities ' unrealized loss recognized charge income removed accumulated comprehensive loss aoci accounts receivable accounts receivable stated net realizable value allowance gross accounts receivable reflects best estimate probable losses inherent receivables portfolio determined basis historical experience specific allowances known troubled accounts currently available information accounts receivable written reasonable means collect full amount including litigation appropriate exhausted allowance million december million december inventories inventories valued lower cost firstin firstout basis market cost includes material conversion costs inventories net consist following december millions finished goods workinprocess materials inventories net property equipment december millions land buildings equipment construction progress property equipment gross less accumulated depreciation property equipment net depreciation property equipment recorded straightline basis estimated useful lives assets estimated useful life buildings ranges years five years equipment leasehold improvements amortized life related facility lease including renewal periods appropriate asset whichever shorter depreciation expense years ended december million million million respectively equipment includes certain computer software software development costs incurred connection developing obtaining software internal use amortized three years assets capital leases included property equipment consolidated balance sheets material litigation loss contingency provisions recorded probable losses probable liability incurred amount liability reasonably estimated based existing information best estimate made minimum loss contingency amount probable range recorded legal fees expensed incurred product liability abbvie accrues product liability claims undiscounted basis probable liability incurred amount liability reasonably estimated based existing information liabilities adjusted quarterly additional information becomes available receivables insurance recoveries product liability claims recorded assets undiscounted basis probable recovery realized business combinations results operations acquired companies included abbvie 's results operations beginning respective acquisition dates assets acquired liabilities assumed recognized date acquisition respective fair values excess fair value consideration transferred estimated fair values net assets acquired recognized goodwill contingent consideration recognized estimated fair value acquisition date determined utilizing probability weighted discounted cash flow model subsequent changes fair value contingent payments recognized income net consolidated statements earnings fair value assets acquired liabilities assumed certain cases may subject revision based final determination fair value legal costs due diligence costs business valuation costs business acquisition costs expensed incurred goodwill intangible assets intangible assets acquired business combination recorded fair value using discounted cash flow model discounted cash flow model requires assumptions timing amount future net cash flows risk cost capital terminal values market participants definitelived intangibles amortized estimated useful lives abbvie reviews recoverability definitelived intangible assets whenever events changes circumstances indicate carrying value asset may recoverable abbvie first compares projected undiscounted cash flows generated asset carrying value undiscounted cash flows intangible asset less carrying value intangible asset intangible asset written fair value usually discounted cash flow amount loss recorded equal excess asset 's net carrying value fair value cash flows identified individual asset review applied lowest level cash flows largely independent cash flows assets liabilities goodwill indefinitelived assets amortized subject impairment review annually frequently indicators impairment exist impairment goodwill would occur carrying amount reporting unit exceeded fair value reporting unit indefinitelived intangible assets consist capitalized iprd would occur fair value iprd intangible asset less carrying amount company tests goodwill impairment first assessing qualitative factors determine whether likely fair value less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative impairment test performed abbvie tests indefinitelived intangible assets using quantitative impairment test quantitative impairment tests company uses estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use foreign currency exchange rates selection appropriate discount rate asset groupings assumptions estimates estimates assumptions used consistent company 's business plans market participant 's views company similar companies use alternative estimates assumptions could increase decrease estimated fair value assets potentially result different impacts company 's results operations actual results may differ company 's estimates based upon company 's recent annual impairment test performed third quarter company concluded goodwill impaired abbvie recorded impairment charge million related certain onmarket product rights japan due increased generic competition charge included cost products sold abbvie recorded impairment charges million certain projects development charges included rd expense impairment charges recorded acquired inprocess research development initial costs rights iprd projects acquired asset acquisition expensed iprd unless project alternative future use costs include initial payments incurred prior regulatory approval connection research development collaboration agreements provide rights develop manufacture market andor sell pharmaceutical products fair value iprd projects acquired business combination capitalized accounted indefinitelived intangible assets underlying project receives regulatory approval point intangible asset accounted definitelived intangible asset discontinuation point intangible asset written development costs incurred acquisition expensed incurred indefinite definitelived assets subject impairment reviews discussed previously foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using period end exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized comprehensive loss income net assets subsidiaries highly inflationary economies remeasured functional currency reporting currency remeasurement recognized earnings immaterial years presented derivatives derivative instruments recognized either assets liabilities fair value abbvie 's balance sheets classified current longterm based scheduled maturity instrument accounting changes fair value derivative instrument depends whether formally designated qualifies part hedging relationship applicable accounting standards type hedging relationship derivatives formally designated hedges company assesses inception quarterly thereafter whether hedging derivatives highly effective offsetting changes fair value cash flows hedged item changes fair value derivative designated fair value hedge hedged item attributable hedge risk recognized earnings immediately fair value hedges used hedge interest rate risk associated certain company 's fixedrate debt effective portions changes fair value derivative designated cash flow hedge reported accumulated comprehensive loss subsequently recognized earnings consistent underlying hedged item cash flow hedges used manage exposures changes foreign currency exchange rates derivatives designated qualify hedges adjusted fair value current earnings determined derivative longer highly effective hedge company discontinues hedge accounting prospectively gains losses immediately reclassified accumulated comprehensive loss earnings relating hedged forecasted transactions longer probable occurring gains losses relating terminations effective cash flow hedges forecasted transactions still probable occurring deferred recognized consistent income loss recognition underlying hedged items terminations fair value hedges result fair value adjustments hedged items date termination new bases accreted par value date maturity derivatives including designated hedge principally classified operating section consolidated statements cash flows consistent underlying hedged item refer note information regarding abbvie 's derivative hedging activities recent accounting pronouncements may financial accounting standards board issued accounting standards update asu summary amendments create revenue contracts customers topic assets deferred costscontracts customers subtopic amendments asu supersede current revenue recognition requirements core principal new guidance entity recognize revenue depict transfer promised goods services customers amount reflects consideration entity expects entitled exchange goods services guidance effective annual reporting periods beginning december including interim periods within reporting period early application permitted abbvie apply amendments using one following two methods retrospectively prior reporting period presented ii retrospectively cumulative effect initially applying amendments recognized date initial application abbvie currently assessing impact adopting guidance consolidated financial statements note supplemental financial information interest expense net years ended december millions interest expense interest dividend income interest expense net interest expense net included million financing related fees incurred connection terminated proposed combination shire income net income net includes income resolution certain contractual agreements fair value adjustments contingent consideration impairments equity securities income net primarily consisted income million resolution contractual agreement accounts payable accrued liabilities december millions sales rebates accounts payable due abbott laboratories dividends payable salaries wages commissions royalty license arrangements accounts payable accrued liabilities longterm liabilities december millions deferred income taxes pension postemployment benefits longterm liabilities note termination proposed combination shire october abbvie 's board directors withdrew previous recommendation abbvie stockholders favor proposed combination shire plc company incorporated jersey shire recommended stockholders vote proposed combination october abbvie shire mutually agreed terminate proposed combination yearended december company incurred transaction financingrelated costs totaling billion billion recorded sga expense million recorded interest expense included sga expense break fee billion tax deductible paid abbvie shire october result termination proposed combination addition company recorded million net foreign exchange losses primarily due undesignated forward contracts entered hedge anticipated foreign currency cash outflows associated terminated proposed combination shire exit certain foreign currency positions forward contracts settled abbvie expects record additional foreign exchange losses million first quarter reflect completed liquidation remaining foreign currency positions refer note information regarding forward contracts note information regarding certain credit facilities entered anticipation proposed combination shire note earnings per share periods subsequent separation abbvie calculated basic earnings per share eps pursuant twoclass method twoclass method earnings allocation formula determines earnings per share common stock participating securities according dividends declared participation rights undistributed earnings method earnings distributed undistributed allocated common shares participating securities based respective rights receive dividends addition participating securities may include certain performancebased awards may otherwise excluded calculation eps treasurystock method abbvie 's forfeitable restricted stock units rsus restricted stock awards rsas including performancebased awards participate dividends basis common shares dividends nonforfeitable holder declared result forfeitable rsus rsas meet definition participating security dilutive effect participating securities calculated using dilutive treasury stock twoclass method years ended december twoclass method dilutive dilutive effect outstanding rsus rsas years ended december approximately million million respectively excluded denominator calculation diluted eps awards otherwise would included calculation eps treasury stock method additionally earnings distributed undistributed allocable participating securities including performancebased awards otherwise included calculation eps treasurystock method excluded numerator calculation basic diluted earnings per share twoclass method earnings allocable participating securities years ended december approximately million million respectively years ended december approximately million million common shares issuable stockbased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive periods prior separation numerator basic diluted eps net earnings attributable abbvie denominator basic diluted eps calculated using million abbvie common shares outstanding immediately following separation number shares used calculate basic diluted earnings per share since abbvie equity awards outstanding prior separation note acquisitions collaborations arrangements cash outflows related collaborations acquisition product rights arrangements totaled million million million respectively abbvie recorded iprd charges million million million respectively abbvie also recorded expenses million related collaboration significant arrangements impacting require contingent milestone payments summarized addition significant arrangements described abbvie entered several arrangements resulting charges iprd million million upon achievement certain development regulatory commercial milestones could make additional payments million million related arrangements entered respectively possible predict reasonable certainty whether milestones achieved timing achievement significant arrangements impacting require contingent milestone payments include following calico life sciences llc september abbvie calico life sciences llc calico entered novel rd collaboration agreement discover develop commercialize new therapies patients agerelated diseases including neurodegeneration cancer abbvie recorded million expense consolidated statement operations related commitments agreement million paid million paid early calico responsible research early development first five years continue advance collaboration projects phase ten year period abbvie option exclusively license collaboration compounds completion phase abbvie support calico early rd efforts upon option exercise would responsible latestage development commercial activities collaboration costs profits shared equally companies post option exercise infinity pharmaceuticals inc september abbvie entered global collaboration agreement infinity pharmaceuticals inc infinity develop commercialize duvelisib ipi treatment patients cancer part agreement abbvie made initial upfront payment million expensed iprd third quarter upon achievement certain development regulatory commercial milestones abbvie could make additional payments million united states companies jointly commercialize duvelisib share equally potential profits outside united states abbvie responsible commercialization duvelisib infinity eligible receive tiered doubledigit royalties net product sales ablynx nv september abbvie entered global collaboration agreement ablynx nv develop commercialize antiilr nanobody alx treatment inflammatory diseases including rheumatoid arthritis systemic lupus erythematosus resulting charge iprd million upon achievement certain development regulatory commercial milestones abbvie could make additional payments million well royalties net sales galapagos nv september abbvie recorded charge iprd million result entering global collaboration galapagos nv galapagos discover develop commercialize cystic fibrosis therapies upon achievement certain development regulatory commercial milestones abbvie could make additional payments million well royalties net sales february abbvie recorded charge iprd million result entering global collaboration galapagos develop commercialize nextgeneration oral janus kinase jak inhibitor phase development potential treat multiple autoimmune diseases additional payments approximately billion could required achievement certain development regulatory commercial milestones agreement alvine pharmaceuticals inc may abbvie entered global collaboration alvine pharmaceuticals inc develop alv novel oral treatment patients celiac disease part agreement abbvie made initial upfront payment million expensed iprd second quarter abbvie could make additional payments totaling million pursuant arrangement action pharma may abbvie recorded charge iprd million result acquisition abt previously referred ap drug development prevention acute kidney injury associated major cardiac surgery patients increased risk note goodwill intangible assets goodwill carrying amount goodwill billion billion december respectively changes goodwill balance primarily due foreign currency translation changes goodwill balance attributable foreign currency translation goodwill additions million related product rights acquired second quarter december accumulated goodwill impairment losses future impairment tests goodwill performed annually third quarter earlier indicators impairment exist intangible assets net following table summarizes abbvie 's intangible assets december december gross net gross net carrying accumulated carrying carrying accumulated carrying millions amount amortization amount amount amortization amount definitelived intangible assets developed product rights license agreements total definitelived intangible assets indefinitelived research development total intangible assets intangible assets finite useful lives amortized estimated useful lives range years average years years developed product rights license agreements respectively additions primarily related acquisition million amortizable intangible assets license agreements onmarket product rights united states average amortization period years amortization expense million million million respectively included cost products sold consolidated statements earnings december anticipated annual amortization expense intangible assets recorded december million million million million million third quarter impairment charge million recorded related certain onmarket product rights japan due increased generic competition charge based discounted cash flow analysis included cost products sold indefinitelived intangible assets december relate iprd acquired business combination abbvie recorded impairment charge million certain projects development charge based discounted cash flow analysis included rd expense material impairment charges recorded related indefinitelived intangible assets note restructuring plans prior years abbvie management approved plans realign worldwide manufacturing operations selected domestic international commercial rd operations order reduce costs conjunction loss expected loss exclusivity certain products restructuring charges recorded million primarily recorded cost products sold consolidated statements earnings remainder recorded sga included charges cash costs million primarily related employee severance contractual obligations abbvie management approved plans restructure certain commercial operations conjunction loss expected loss exclusivity certain products restructuring charges recorded million primarily recorded sga cost products sold consolidated statements earnings remainder recorded rd included charges cash costs million mainly related employee severance contractual obligations abbvie management approved plans realign worldwide manufacturing operations selected domestic international commercial rd operations order reduce costs abbvie incurred restructuring charges approximately million employee severance contractual obligations primarily related exit rd facility million recorded within rd million within sga expenses consolidated statements earnings following summarizes cash activity restructuring reserve years ended december millions accrued balance december restructuring charges payments adjustments accrued balance december restructuring charges payments adjustments accrued balance december restructuring charges payments adjustments accrued balance december payments adjustments included million reversal previously recorded restructuring reserve due company 's reevaluation prior year decision exit manufacturing facility abbvie recorded additional restructuring charges million primarily accelerated depreciation note debt credit facilities commitments contingencies following summary longterm debt december effective effective interest rate interest rate millions floating rate notes due notes due notes due notes due notes due notes due fair value hedges unamortized bond discounts total longterm debt lease obligations current portion noncurrent portion excludes effect related interest rate swaps november abbvie issued billion aggregate principal amount senior notes approximately billion senior notes issued abbott partial consideration transfer assets abbott abbvie abbvie used part net proceeds sale senior notes senior notes issued abbott finance payment made november billion distribution abbott provided terms separation agreement debt guaranteed abbott abbvie separated abbott january abbvie may redeem senior notes series floating notes due time senior notes series floating notes due time time redemption price equal principal amount senior notes redeemed plus makewhole premium abbvie may redeem floating notes due prior maturity december company compliance senior note covenants shortterm borrowings december shortterm borrowings included million million respectively commercial paper borrowings weightedaverage interest rate shortterm borrowings respectively prior october abbvie billion unsecured fiveyear revolving credit facility agreement october abbvie replaced existing revolving credit facility billion fiveyear revolving credit facility also supports commercial paper borrowings december abbvie compliance financial covenants borrowings outstanding facilities december december maturities longterm debt capital lease obligations following table summarizes abbvie 's future minimum lease payments noncancelable operating leases debt maturities future minimum lease payments capital lease obligations december operating debt maturities years ended december millions leases capital leases thereafter total obligations commitments fair value hedges unamortized bond discounts na total debt lease obligations lease expense million million material part separation abbvie entered agreements lease certain facilities including office laboratory factory warehouse space principally noncancelable operating leases abbott abbvie 's operating leases generally include renewal options provide company pay taxes maintenance insurance operating costs leased property capital lease obligations relate automobiles certain facilities december annual future minimum lease payments capital lease obligations material debt maturities capital leases include million floating notes due maturities billion senior notes contingencies guarantees connection separation abbvie indemnified abbott liabilities resulting operation abbvie 's business income tax liabilities respect periods prior distribution date liabilities agreed abbvie abbott abbvie material exposures offbalance sheet arrangements specialpurpose entities activities included nonexchangetraded contracts accounted fair value ordinary course business abbvie periodically entered thirdparty agreements assignment product rights resulted abbvie becoming secondarily liable obligations abbvie previously primarily liable based upon past experience likelihood payments agreements remote abbvie periodically acquires business product rights abbvie agrees pay contingent consideration based attaining certain thresholds based occurrence certain events note financial instruments fair value measures risk management policy company exposed foreign currency exchange rate interest rate risks related business operations company 's hedging policy attempts manage risks acceptable level based company 's judgment appropriate tradeoff risk opportunity costs company uses derivative instruments reduce exposure foreign currency exchange rates company also exposed risk earnings cash flows could adversely impacted fluctuations interest rates company periodically enters interest rate swaps based judgment manage interest costs company agrees exchange specified intervals difference fixed floating interest amounts calculated reference agreedupon notional amount derivative instruments used trading purposes manage exposure changes interest rates investment securities none company 's outstanding derivative instruments contain credit risk related contingent features collateral generally required financial instruments various abbvie foreign subsidiaries enter foreign currency forward exchange contracts manage exposures changes foreign exchange rates anticipated intercompany transactions denominated currency functional currency local entity contracts notional amounts totaling billion billion december december respectively designated cash flow hedges recorded fair value accumulated gains losses december included cost products sold time products sold generally exceeding twelve months company enters foreign currency forward exchange contracts manage exposure foreign currency denominated trade payables receivables intercompany loans contracts markedtomarket resulting gains losses reflected income generally offset losses gains foreign currency exposure managed december december abbvie held notional amounts billion billion respectively foreign currency forward exchange contracts company entered undesignated forward contracts total notional amount billion hedge anticipated foreign currency cash outflows associated terminated proposed combination shire large portion contracts original maturity first quarter net settled fourth quarter company realized million net foreign exchange loss associated shirerelated forward contracts abbvie party interest rate hedge contracts designated fair value hedges totaling billion december december effect hedge change fixedrate interest obligation floating rate portion debt abbvie recorded contracts fair value adjusted carrying amount fixedrate debt offsetting amount following table summarizes amounts location abbvie 's derivative instruments december fair valuederivatives liability fair valuederivatives asset position position millions balance sheet caption balance sheet caption interest rate swaps designated fair value hedges na longterm liabilities foreign currency forward exchange contracts prepaid expenses accounts payable accrued hedging instruments liabilities prepaid expenses accounts payable accrued others designated hedges liabilities total certain derivatives subject netting arrangements company 's counterparties company offset derivative assets liabilities within consolidated balance sheets following table summarizes activity derivative instruments amounts location income expense gain loss reclassified net earnings years ended december respectively amount hedge ineffectiveness significant years ended december gain loss recognized expense income loss gain comprehensive reclassified loss income income millions income statement caption foreign currency forward exchange contracts designated cash flow hedges cost products sold net foreign exchange loss designated hedges na na na gain interest rate swaps designated fair value hedges na na na interest expense income net gainloss related fair value hedges recognized net interest expense directly offsets lossgain underlying hedged item fixedrate debt resulting net impact net interest expense years ended december fair value measures fair value hierarchy accounting standard fair value measurements consists following three levels level valuations based unadjusted quoted prices active markets identical assets company ability access level valuations based quoted prices similar instruments active markets quoted prices identical similar instruments markets active modelbased valuations significant inputs observable market level valuations using significant inputs unobservable market include use judgment company 's management assumptions market participants would use pricing asset liability following table summarizes bases used measure certain assets liabilities carried fair value recurring basis consolidated balance sheet december basis fair value measurement quoted prices active significant markets significant balance identical observable unobservable december assets inputs inputs millions level level level assets cash equivalents time deposits equity securities foreign currency contracts total assets liabilities interest rate hedges foreign currency contracts total liabilities following table summarizes bases used measure certain assets liabilities carried fair value recurring basis consolidated balance sheet december basis fair value measurement quoted prices active significant markets significant balance identical observable unobservable december assets inputs inputs millions level level level assets cash equivalents time deposits equity securities foreign currency contracts total assets liabilities interest rate hedges foreign currency contracts contingent consideration total liabilities fair values time deposits included cash equivalents shortterm investments determined based discounted cash flow analysis reflecting quoted market rates similar instruments fair values time deposits approximate amortized cost due short maturities instruments availableforsale equity securities consists investments fair value determined using published market price per unit multiplied number units held without consideration transaction costs derivatives entered company valued using publicized spot curves interest rate hedges publicized forward curves foreign currency contracts contingent consideration valued using discounted cash flow technique reflects management 's expectations probability payment cumulative net unrealized holding gains availableforsale equity securities totaled million million december december respectively transfers assets liabilities fair value measurement levels following table reconciliation fair value measurements use significant unobservable inputs level consist contingent payments related acquisitions investments millions fair value december payments additions change fair value recognized earnings fair value december payments change fair value recognized earnings fair value december contingent payments primarily connection acquisition solvay 's us pharmaceuticals business achievement certain sales milestone resulted payment approximately million million liability previously established additions million related acquisition product rights change fair value recognized earnings recognized net foreign exchange loss income net consolidated statements earnings addition financial instruments company required recognize fair value consolidated balance sheets company certain financial instruments recognized historical cost basis fair value carrying values fair values certain financial instruments december shown table approximate book values fair values millions assets investments liabilities shortterm borrowings current portion longterm debt lease obligations longterm debt lease obligations excluding fair value hedges following table summarizes bases used measure approximate fair values financial instruments december basis fair value measurement quoted prices active significant markets significant fair value identical observable unobservable december assets inputs inputs millions level level level assets investments total assets liabilities shortterm borrowings current portion longterm debt lease obligations longterm debt lease obligations excluding fair value hedges total liabilities following table summarizes bases used measure approximate fair values financial instruments december basis fair value measurement quoted prices active significant markets significant fair value identical observable unobservable december assets inputs inputs millions level level level assets investments total assets liabilities shortterm borrowings current portion longterm debt lease obligations longterm debt lease obligations excluding fair value hedges total liabilities investments consist cost method investments heldtomaturity debt securities cost method investments include certain investments fair value determined using published market price per unit multiplied number units held without consideration transaction costs determine fair value cost method investments company takes consideration recent transactions well financial information investee represents level basis fair value measurement fair value heldtomaturity debt securities estimated based upon quoted market prices similar debt instruments fair values shortterm current borrowings approximate carrying values due short maturities instruments fair value longterm debt excluding fair value hedges determined using published market price debt instruments without consideration transaction costs represents level basis fair value measurement counterparties financial instruments consist select major international financial institutions concentrations risk company invests excess cash time deposits money market funds us treasury securities diversifies concentration cash among different financial institutions company monitors concentrations credit risk associated deposits financial institutions credit exposure limits established limit concentration single issuer institution december abbvie approximately million net monetary assets denominated venezuelan bolivar converted rate vefusd venezuelan entity net sales million abbvie 's net monetary assets denominated venezuelan bolivar converted rate vefusd december would resulted devaluation loss million company predict whether devaluations venezuelan currency whether use official rate continue supported evolving facts circumstances circumstances change company concludes would appropriate use different rate devaluation official rate occurs could result significant change abbvie 's results operations three us wholesalers accounted percent percent total net accounts receivable december december respectively substantially abbvie 's sales united states three wholesalers addition net governmental receivables outstanding greece portugal italy spain totaled million december million december humira abbvie 's single largest product accounted approximately percent percent percent abbvie 's total net sales respectively note postemployment benefits abbvie sponsors various pension postemployment benefit plans including defined benefit defined contribution termination indemnity plans cover employees worldwide addition abbvie provides medical benefits primarily eligible us retirees postretirement benefit plans net obligations plans reflected consolidated balance sheets december abbott sponsored plans prior separation abbvie employees participated certain us international defined benefit pension postemployment benefit opeb plans sponsored abbott plans included participants abbott 's businesses accounted multiemployer benefit plans abbvie 's combined financial statements year ended december result asset liability recorded abbvie historical combined balance sheets december recognize funded status plans effective january connection separation abbvie abbott plans separated abbvie assumed net benefit plan obligations previously provided abbott abbottsponsored defined benefit postemployment benefit plans abbvie recorded expenses million abbott made voluntary contributions defined benefit pension plans abbvie accounted multiemployer benefit plans totaling million abbvie sponsored plans prior separation abbvie employees participated abbott laboratories annuity retirement plan abbott 's principal domestic defined benefit pension plan connection separation abbvie established abbvie pension plan abbvie 's principal domestic defined benefit pension plan substantially terms abbott laboratories annuity retirement plan abbvie employees eligible participate abbott laboratories annuity retirement plan december automatically became eligible abbvie pension plan first quarter abbvie pension plan assumed obligations related assets employees abbott laboratories annuity retirement plan abbvie made voluntary contributions million million respectively plan abbvie also made voluntary contribution million plan subsequent december benefit plan information table pertains global abbviesponsored defined benefit pension postemployment plans defined postemployment benefit plans plans years ended december millions projected benefit obligations beginning period service cost interest cost employee contributions plan amendments assumption plan liabilities removal plans actuarial gain loss benefits paid primarily foreign currency translation loss end period fair value plan assets beginning period actual return plan assets company contributions employee contributions assumption plan assets benefits paid primarily foreign currency translation gain end period funded status december amounts recognized consolidated balance sheets assets current liabilities longterm liabilities net liability december actuarial losses net prior service cost aoci december projected benefit obligations pbo table included billion billion december respectively related international defined benefit pension plans number generally funded accordance local regulations benefit payments plans funded company assets funded status december reflects abbvie considered release new mortality tables projection scales society actuaries improvement estimate future mortality opted change new tables plans reflected table accumulated benefit obligations abo billion billion december respectively plans reflected table abo exceeded plan assets december abo pbo aggregate plan assets billion billion billion respectively amounts recognized aoci oci defined benefit pension postemployment plans ' actuarial gains losses prior service costs credits yet recognized net periodic benefit cost recognized netoftax basis aoci amortized net periodic benefit cost future following summary pretax gains losses included oci years ended december millions defined benefit plans actuarial gain loss prior service cost amortization actuarial losses prior service costs foreign exchange loss total pretax gain loss recognized oci postemployment plans actuarial gain loss prior service cost amortization actuarial losses prior service costs total pretax gain loss recognized oci pretax amount actuarial gain loss prior service cost included aoci december expected recognized net periodic benefit cost million defined benefit plans million postemployment plans net periodic benefit cost years ended december millions defined benefit plans service cost interest cost expected return plan assets amortization actuarial losses prior service costs net periodic pension benefit cost postemployment plans service cost interest cost amortization actuarial gain prior service costs net periodic opeb cost weightedaverage assumptions used determining benefit obligations measurement date defined benefit plans discount rate rate compensation increases postemployment plans discount rate rate compensation increases assumptions used calculating december measurement date benefit obligations used calculation net periodic benefit cost weightedaverage assumptions used determining net periodic benefit cost defined benefit plans discount rate expected longterm rate return plan assets expected rate change compensation postemployment plans discount rate na purposes measuring postretirement health care obligations measurement date company assumed pre post annual rate increase per capita cost covered health care benefits rate assumed decrease gradually remain level thereafter purposes measuring postretirement health care costs company assumed pre post annual rate increase per capita cost covered health care benefits rate assumed decrease gradually remain level thereafter assumed health care cost trend rates significant effect amounts reported health care plans december percentage point change assumed health care cost trend rates would following effects one percentage point year ended december millions increase decrease service cost interest cost projected benefit obligation defined benefit pension plan assets basis fair value measurement quoted prices significant significant balance active markets observable unobservable december identical assets inputs inputs millions level level level equities us large capa us mid capb internationalc fixed income securities us government securitiesd corporate debt instrumentse government securities international absolute return fundsf real assets otherg fair value plan assets basis fair value measurement quoted prices significant significant balance active markets observable unobservable december identical assets inputs inputs millions level level level equities us large capa us mid capb internationalc fixed income securities us government securitiesd corporate debt instrumentse government securities international absolute return fundsf real assets otherg fair value plan assets mix pooled index funds actively managed equity accounts benchmarked various large cap indices b mix pooled index funds actively managed equity accounts benchmarked various mid cap indices c mix pooled index funds actively managed equity accounts benchmarked various nonus equity indices developed emerging markets securities held actively managed accounts pooled index funds mutual funds e securities held actively managed accounts pooled index funds mutual funds f funds global mandates flexibility allocate capital broadly across wide range asset classes strategies including limited equities fixed income commodities financial futures currencies securities objectives outperform agreed upon benchmarks specific return volatility targets g investments cash cash equivalents equities valued using quoted prices valued published market prices equities common collective trust registered investment company valued using significant observable inputs valued net asset value nav provided fund administrator nav based value underlying assets owned fund minus liabilities fixed income securities valued using significant observable inputs valued prices obtained independent financial service industryrecognized vendors absolute return funds commodities valued nav provided fund administrator following table summarizes change value plan assets measured using significant unobservable inputs level millions balance january actual return plan assets hand year end assumption level assets purchases sales settlements net balance december investment mix equity securities fixed income asset allocation strategies based upon achieving desired return balancing higher return volatile equity securities lower return less volatile fixed income securities investment allocations established plan generally made across range markets industry sectors capitalization sizes case fixed income securities maturities credit quality target investment allocations abbvie pension plan equity securities fixed income securities asset allocation strategies holdings known significant concentrations risk plan assets abbvie pension plan plans ' assets plans ' expected return assets shown based management 's expectations longterm average rates return achieved underlying investment portfolios establishing assumption management considers historical expected returns asset classes plans invested well current economic capital market conditions expected pension postemployment payments defined postemployment millions benefit plans plans table reflects total benefit payments expected paid participants includes payments funded company assets well paid plans prior separation abbvie employees also participated abbott laboratories stock retirement plan abbott 's principal defined contribution plan abbvie recorded expense million related plan connection separation abbvie established abbvie savings plan abbvie 's principal defined contribution plan substantially terms abbott laboratories stock retirement plan abbvie employees eligible participate abbott laboratories stock retirement plan december automatically became eligible abbvie savings plan abbvie recorded expense million million related plan abbvie provides certain postemployment benefits primarily salary continuation plans qualifying employees accrues related cost service lives employees note equity stockbased compensation stockbased compensation expense million million million respectively principally classified sga periods presented remainder classified rd cost products sold related tax benefit recognized million million million respectively stockbased compensation expense allocated abbvie based portion abbott 's incentive stock program abbvie employees participated compensation expense stockbased awards measured based fair value awards date stockbased awards granted adjusted estimated number awards expected vest forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates compensation cost stockbased awards amortized service period could shorter vesting period employee retirement eligible charge compensation expense stockbased awards granted retirementeligible employees compensation expense recognized immediately grant date employee able retain award without continuing provide service prior separation abbvie employees participated abbott 's incentive stock program abbvie incentive stock program adopted time separation facilitated assumption certain awards granted abbott 's incentive stock program authorizes postseparation grant several different forms benefits including nonqualified stock options rsas rsus performancebased rsas rsus abbvie incentive stock program million shares common stock reserved issuance respect postseparation awards participants connection separation outstanding abbott employee stock options rsas rsus previously issued abbott 's incentive stock program adjusted converted new abbott abbvie stockbased awards using formula designed preserve intrinsic value fair value awards immediately prior separation upon separation january holders abbott stock options rsas rsus generally received one abbvie stock based award abbott stockbased award outstanding adjusted awards retained vesting schedule expiration date original awards abbvie awards granted abbott employees connection separation realized excess tax benefits associated stockbased compensation totaled million million respectively presented consolidated statements cash flows outflow within operating section inflow within financing section stock options exercise price options granted least equal percent market value date grant stock options typically contractual term years generally vest onethird increments threeyear period fair value stock options determined using blackscholes model weightedaverage grantdate fair values stock options granted respectively stockbased compensation expense attributable options years presented material following table summarizes abbvie stock option activity abbvie abbott employees year ended december weighted weighted average average remaining aggregate options thousands aggregate intrinsic value millions options exercise price life years intrinsic value outstanding december granted exercised lapsed outstanding december exercisable december aggregate intrinsic value table represents difference exercise price company 's closing stock price last day trading year ended december total intrinsic value options exercised million million respectively options issued abbott 's incentive stock programs abbvie employees prior separation total intrinsic value options exercises million total fair value options vested million excess tax benefit realized option exercises totaled million december million unrecognized compensation cost related stock options expected recognized expense approximately next two years rsas rsus rsas generally vest three five years rsas vest five years onethird award vests one year rsus vest three years upon vesting recipient receives one share common stock vested rsu addition abbvie grants selected executives key employees performancebased rsas rsus vesting contingent upon meeting various companywide performance goals including abbvie achieving minimum return equity fair value rsas rsus including performancebased awards determined based number shares granted quoted price common stock date grant abbvie assumes performance goals achieved goals met compensation cost recognized previously recognized compensation cost reversed following table summarizes abbvie rsa rsu activity including performancebased awards abbvie abbott employees year ended december weightedaverage share units thousands share units grant date fair value outstanding december granted vested lapsed outstanding december fair market value rsas rsus vested million million respectively rsas rsus issued abbott 's incentive stock programs prior separation fair market value rsas rsus vested million weightedaverage grantdate fair value per share rsas rsus granted amounts adjusted reflect separation abbott december million unrecognized compensation cost related rsas rsus expected recognized expense approximately next two years cash dividends december board directors declared quarterly cash dividend per share common stock stockholders record january paid february additionally quarterly cash dividend declared board directors february per share represented increase percent previous quarterly rate per share paid may june september board directors declared quarterly cash dividends per share paid august november respectively additionally october board directors declared increase company 's quarterly cash dividend per share per share common stock stockholders record january paid february stock repurchase program february abbvie 's board directors authorized billion stock repurchase program october abbvie 's board directors authorized new billion stock repurchase program effective immediately supersedes previous authorization expected executed next several years stock repurchase authorization permits purchases abbvie shares time time open market private transactions management 's discretion depending company 's cash flows net debt level market conditions plan time limit discontinued time abbvie repurchased approximately million shares million shares million million respectively open market shares repurchased program recorded acquisition cost including related expenses available general corporate purposes abbvie 's remaining share repurchase authorization billion december accumulated comprehensive loss following table summarizes changes balances component aoci net tax years ended december unrealized gains foreign pension losses currency post marketable translation employment equity hedging millions brackets denote losses adjustments benefits securities activities total balance december comprehensive income reclassifications amounts reclassified accumulated comprehensive income net currentperiod comprehensive income separationrelated adjustments balance december comprehensive income reclassifications amounts reclassified accumulated comprehensive income net currentperiod comprehensive income separationrelated adjustments balance december comprehensive income reclassifications amounts reclassified accumulated comprehensive income net currentperiod comprehensive loss income balance december comprehensive loss includes foreign currency translation adjustments totaling loss billion principally driven impact substantial weakening euro translation company 's eurodenominated assets ii weakening foreign currencies combination increased concentration cash denominated foreign currencies accumulated anticipation terminated proposed combination shire plc table presents significant amounts reclassified component accumulated comprehensive loss years ended december years ended december millions pension postemployee benefits amortization actuarial losses less tax expense total reclassification net tax hedging activities gains losses designated cash flow hedges less tax expense total reclassification net tax addition common stock abbvie 's authorized capital includes million shares preferred stock par value december shares preferred stock issued outstanding note income taxes earnings income taxes years ended december millions domestic foreign total earnings income taxes increase domestic loss income taxes year ended december driven transaction financingrelated costs associated terminated proposed combination shire refer note information income taxes years ended december millions current domestic foreign total current taxes deferred domestic foreign total deferred taxes total income taxes effective tax rate reconciliation years ended december statutory tax rate state taxes net federal benefit effect foreign operations us tax credits branded prescription drug fee valuation allowances resolution uncertain tax positions nondeductible litigation loss net effective tax rate effective tax rate fluctuates year year due allocation company 's taxable earnings among jurisdictions well certain discrete factors events year including acquisitions collaborations effective tax rate differs statutory tax rate principally due benefit foreign operations reflects impact lower income tax rates locations outside united states tax exemptions incentives puerto rico foreign tax jurisdictions business development activities together cost repatriation decisions effective tax rate periods also reflects benefit us tax credits principally related research development credits orphan drug tax credit puerto rico excise tax credits research development credit due legislation enacted fourth quarter extended credit december increase effective tax rate principally driven additional expenses million related branded prescription drug fee non deductible state tax valuation allowances million discussed deferred tax assets liabilities section following july internal revenue service issued final rules regulations branded prescription drug fee annual nontaxdeductible fee payable federal government affordable care act based allocation company 's market share branded prescription drugs sold certain government programs prior year final rules accelerated expense recognition criteria fee obligation year fee paid year market share used allocate fee determined change required abbvie industry participants recognize additional year expense effective income tax rate reflects income tax expenses relating current earnings outside united states deemed indefinitely reinvested effective income tax rate includes recognition tax benefits totaling approximately million result favorable resolutions various tax positions pertaining prior years puerto rico enacted legislation assesses excise tax beginning certain products manufactured puerto rico tax levied gross inventory purchases entities puerto rico included cost products sold consolidated statements earnings majority tax creditable us income tax purposes deferred tax assets liabilities december millions deferred tax assets compensation employee benefits accruals reserves chargebacks rebates deferred revenue depreciation state income taxes net operating losses credit carryforwards total deferred tax assets valuation allowances total net deferred tax assets deferred tax liabilities excess book basis tax basis intangible assets repatriation foreign earnings total deferred tax liabilities net deferred tax asset gross federal net operating loss carryforwards december million available use gross state net operating loss tax credit carryforwards december billion million respectively state tax carryforwards expire periods december foreign net operating loss carryforwards million majority foreign loss carryforwards expiration period december company valuation allowances million million respectively principally related state net operating losses credit carryforwards expected realized deferred income taxes provided approximately billion undistributed earnings foreign subsidiaries earnings indefinitely reinvested continued use foreign operations due complexities tax laws assumptions would made practicable estimate amount income taxes would due earnings distributed unrecognized tax benefits years ended december millions balance january increase due current year tax positions increase due prior year tax positions decrease due prior year tax positions settlements lapse statutes limitations separationrelated adjustments balance december abbvie abbott entered tax sharing agreement effective date separation provides abbott liable indemnified abbvie income tax liabilities periods prior separation table reflects reduction billion relating tax periods prior separation abbott primary obligor however us treasury regulations member consolidated group severally liable us federal income tax liability member consolidated group accordingly respect periods abbvie included abbott 's consolidated group abbvie could liable us government us federal income tax liability incurred consolidated group extent discharged member however liability imposed abbvie would entitled indemnified abbott pursuant tax sharing agreement abbvie responsible unrecognized tax benefits related interest penalties periods separation instances existing entity transferred abbvie upon separation result abbvie continued account tax uncertainties extent obligations relate periods prior separation reimbursement receivable approximately million recorded within assets december recognized net amount potential tax benefits would impact company 's effective tax rate million million respectively company routinely audited tax authorities significant jurisdictions number audits currently underway reasonably possible next twelve months uncertain tax positions may settled could result decrease gross amount unrecognized tax benefits due potential resolution federal state foreign examinations expiration various statutes limitation company 's gross unrecognized tax benefits balance may change within next twelve months million significant federal state local international matters concluded years company believes adequate provision made income tax uncertainties abbvie recognizes accrued interest penalties related uncertain tax positions income tax expense amounts expensed liabilities accrued immaterial years ended december uncertain tax positions generally included longterm liability consolidated balance sheets note legal proceedings contingencies subject certain exceptions specified separation agreement abbvie assumed liability control pending threatened legal matters related business including liabilities claims legal proceedings related products part business discontinued prior distribution well assumed retained liabilities indemnify abbott liability arising resulting assumed legal matters abbvie involved various claims legal proceedings investigations including described recorded accrual balance litigation december significant within next year legal proceedings may occur may result change estimated loss accrued abbvie feasible predict outcome proceedings exposures certainty management believes ultimate disposition material adverse effect abbvie 's consolidated financial position cash flows results operations several pending lawsuits filed unimed pharmaceuticals inc solvay pharmaceuticals inc company abbott acquired february known abbvie products llc others consolidated pretrial purposes united states district court northern district georgia multi district litigation rules androgel antitrust litigation mdl cases brought private plaintiffs federal trade commission ftc generally allege solvay 's patent litigation involving androgel sham litigation patent litigation settlement agreement related agreements three generic companies violate federal state antitrust laws state consumer protection unjust enrichment laws plaintiffs generally seek monetary damages andor injunctive relief attorneys ' fees mdl includes three individual plaintiff lawsuits b seven purported class actions c federal trade commission v watson pharmaceuticals inc et al filed may united states district court northern district georgia following district court 's dismissal plaintiffs ' claims appellate proceedings led reinstatement claims regarding patent litigation settlement proceeding discovery district court september federal trade commission ftc filed suit united states district court eastern district pennsylvania abbvie others alleging patent litigation two generic companies regarding androgel sham litigation patent litigation settlement one generic companies violates federal antitrust laws ftc 's complaint seeks monetary damages injunctive relief august putative class action lawsuit sidney hillman health center rochester et al v abbvie inc et al filed abbvie united states district court northern district illinois three healthcare benefit providers alleging violations federal rico statutes state deceptive business practice unjust enrichment laws connection reimbursements certain uses depakote plaintiffs seek monetary damages andor equitable relief attorneys ' fees august district court dismissed plaintiffs ' claims prejudice plaintiffs appealed district court 's decision united states court appeals seventh circuit matter currently pending lawsuits filed abbvie others generally alleging patent litigation settlement involving niaspan entered kos pharmaceuticals inc company acquired abbott laboratories presently subsidiary abbvie generic company violates federal state antitrust laws state unfair deceptive trade practices unjust enrichment laws plaintiffs generally seek monetary damages andor injunctive relief attorneys ' fees september pending putative class action lawsuits centralized consolidated coordinated pretrial proceedings united states district court eastern district pennsylvania multidistrict litigation rules niaspan antitrust litigation mdl november glaxosmithkline filed lawsuit abbott laboratories united states district court northern district california alleging abbott violated antitrust laws connection norvir repricing march jury found abbott violate antitrust laws breached license agreement plaintiff january judge panel united states court appeals ninth circuit reversed verdict remanded case new trial due alleged improper exclusion potential juror case returned trial court proceedings abbvie assumed liability control proceeding connection separation abbott abbvie seeking enforce patent rights relating testosterone gel drug abbvie sells trademark androgel case filed united states district court district delaware february abbvie alleges perrigo company 's perrigo israel pharmaceutical ltd 's proposed generic product infringes abbvie patents seeks declaratory injunctive relief second case filed united states district court district delaware march abbvie alleges watson laboratories inc 's actavis inc 's proposed generic product infringes abbvie 's patents seeks declaratory injunctive relief november abbvie watson actavis entered confidential settlement license agreement litigation dismissed stipulation parties abbvie seeking enforce patent rights relating ritonavirlopinavir tablets drug abbvie sells trademark kaletra case filed united states district court northern district illinois march abbvie alleges matrix laboratories inc 's matrix laboratories ltd 's mylan inc 's proposed generic products infringe abbvie 's patents seeks declaratory injunctive relief upon matrix 's motion november court granted fiveyear stay litigation unless good cause lift stay shown july stay lifted pursuant original terms court order entered abbvie seeking enforce patent rights relating ritonavir tablets drug abbvie sells trademark norvir case pending united states district court southern district ohio since april abbvie alleges roxane laboratories inc 's roxane proposed generic product infringes abbvie 's patents seeks declaratory injunctive relief another case filed united states district court southern district ohio july abbvie alleges roxane 's proposed generic ritonavir product infringes additional abbvie patents seeks declaratory injunctive relief additional patents september abbvie roxane entered settlement license agreement date license confidential parties entered stipulation dismiss ohio litigation separate case filed united states district court district delaware may abbvie alleges hetero usa inc 's hetero labs limited 's proposed generic ritonavir tablets product infringes abbvie 's patents seeks declaratory injunctive relief november abbvie hetero entered confidential settlement license agreement litigation dismissed stipulation parties separate case filed united states district court district delaware july abbvie alleges aurobindo pharma limited aurobindo pharma usa inc 's proposed generic ritonavir tablets product infringes abbvie 's patents seeks declaratory injunctive relief december abbvie aurobindo entered confidential settlement license agreement litigation dismissed stipulation parties separate case filed united states district court district delaware october abbvie alleges mylan pharmaceutical inc 's proposed generic ritonavir tablets product infringes abbvie 's patents seeks declaratory injunctive relief abbvie seeking enforce certain patent rights cover use fully human antitnf alpha antibodies methotrexate treat rheumatoid arthritis case filed united states district court district massachusetts may abbvie alleges centocor ortho biotech inc 's janssen biotech inc 's product simponi infringes abbvie 's patents seeks damages injunctive relief december parties entered settlement license agreement terms confidential litigation dismissed prejudice november five individuals filed putative class action lawsuit behalf purchasers sellers certain shire plc securities june october abbvie chief executive officer united states district court northern district illinois alleging defendants made andor responsible material misstatements violation federal securities laws connection abbvie 's proposed transaction shire complaint seeks unspecified monetary damages injunctive relief november putative class action lawsuit medical mutual ohio v abbvie inc et al filed several manufacturers testosterone replacement therapies trts including abbvie united states district court northern district illinois behalf insurance companies health benefit providers thirdparty payors paid trts including androgel claims asserted include violations federal racketeer influenced corrupt organizations act state consumer fraud deceptive trade practices laws complaint seeks unspecified monetary injunctive relief december shareholder derivative lawsuit plumbers steamfitters local pension plans v jp morgan securities llc et al filed delaware chancery court alleging abbvie 's directors breached fiduciary duties connection shire transaction approval termination lawsuit seeks unspecified compensatory damages abbvie among relief note segment geographic area information abbvie operates one business segmentpharmaceutical products substantially abbvie 's us sales three wholesalers outside united states products sold primarily health care providers distributors depending market served worldwide net sales key products follows years ended december millions humira androgel kaletra synagis lupron synthroid sevoflurane creon dyslipidemia products duodopa viekira net sales net sales external customers based country sold product follows years ended december millions united states germany netherlands united kingdom france japan canada spain brazil italy countries net sales longlived assets include net property equipment billion billion december billion billion respectively located united states puerto rico million million respectively located europe note quarterly financial data unaudited millions except per share data first quarter net sales gross margin net earnings basic earnings per share diluted earnings per share cash dividends declared per common share second quarter net sales gross margin net earnings basic earnings per share diluted earnings per share cash dividends declared per common share third quarter net sales gross margin net earnings basic earnings per share diluted earnings per share cash dividends declared per common share fourth quarter net sales gross margin net loss earnings b basic loss earnings per share c diluted loss earnings per share c cash dividends declared per common share january cash dividend per share common stock declared preseparation earnings recorded reduction additional paidin capital refer note additional information regarding cash dividends declared b results fourth quarter include transaction financingrelated costs incurred connection terminated proposed combination shire million aftertax charge related research development collaboration agreement calico million aftertax charge result entering global collaboration infinity refer notes information relating termination proposed combination shire collaborations calico infinity respectively c basic loss per share fourth quarter calculated treasurystock method dilutive approximately million common shares excluded computation diluted loss per share assuming dilution effect would antidilutive report independent registered public accounting firm board directors shareholders abbvie inc audited accompanying consolidated balance sheet abbvie inc subsidiaries december related consolidated statements earnings comprehensive income equity cash flows years ended financial statements responsibility company 's management responsibility express opinion financial statements based audit conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position abbvie inc subsidiaries december consolidated results operations cash flows years ended conformity us generally accepted accounting principles also audited accordance standards public company accounting oversight board united states abbvie inc subsidiaries ' internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon ernst young llp chicago illinois february report independent registered public accounting firm board directors shareholders abbvie inc audited accompanying combined statements earnings comprehensive income equity cash flows abbvie inc subsidiaries company year ended december combined financial statements responsibility company 's management responsibility express opinion financial statements based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether combined financial statements free material misstatement company required engaged perform audit internal control financial reporting audit included consideration internal control financial reporting basis designing audit procedures appropriate circumstances purpose expressing opinion effectiveness company 's internal control financial reporting accordingly express opinion audit also includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audit provide reasonable basis opinion opinion combined financial statements present fairly material respects results operations cash flows company year ended december conformity accounting principles generally accepted united states america described note accompanying combined financial statements derived consolidated financial statements accounting records abbott laboratories combined financial statements also include expense allocations certain corporate functions historically provided abbott laboratories allocations may reflective actual expense would incurred company operated separate entity apart abbott laboratories deloitte touche llp chicago illinois march item changes disagreements accountants accounting financial disclosure none item controls procedures disclosure controls procedures evaluation disclosure controls procedures chief executive officer richard gonzalez chief financial officer william j chase evaluated effectiveness abbvie 's disclosure controls procedures end period covered report concluded abbvie 's disclosure controls procedures effective ensure information abbvie required disclose reports files submits securities exchange commission securities exchange act recorded processed summarized reported within time periods specified commission 's rules forms ensure information required disclosed abbvie reports files submits exchange act accumulated communicated abbvie 's management including principal executive officer principal financial officer appropriate allow timely decisions regarding required disclosure internal control financial reporting management 's annual report internal control financial reporting management 's report internal control financial reporting included hereof report abbvie 's independent registered public accounting firm related assessment effectiveness internal control financial reporting included hereof changes internal control financial reporting part separation abbott abbvie began phased global implementation new enterprise resource planning system related technology infrastructure transaction processing services replace information technology infrastructure transactional services provided abbvie abbott various transition services agreements initiatives expected completed include modifications design operation controls financial reporting abbvie reviews controls design effectiveness prior implementation phase changes abbvie 's internal control financial reporting defined rule af exchange act materially affected reasonably likely materially affect abbvie 's internal control financial reporting quarter ended december inherent limitations effectiveness controls abbvie 's management including chief executive officer chief financial officer expect abbvie 's disclosure controls internal control financial reporting prevent detect errors fraud control system matter well designed operated provide reasonable absolute assurance control system 's objectives met design control system must reflect fact resource constraints benefits controls must considered relative costs inherent limitations control systems evaluation controls provide absolute assurance misstatements due error fraud occur control issues instances fraud detected inherent limitations include realities judgments decisionmaking faulty breakdowns occur simple error mistake controls also circumvented individual acts persons collusion two people management override controls design system controls based part certain assumptions likelihood future events assurance design succeed achieving stated goals potential future conditions projections evaluation controls effectiveness future periods subject risks time controls may become inadequate changes conditions deterioration degree compliance policies procedures item b information none management 's report internal control financial reporting management abbvie responsible establishing maintaining adequate internal control financial reporting term defined rule f securities exchange act abbvie 's internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states however internal control systems matter well designed inherent limitations therefore even systems determined effective provide reasonable assurance respect financial statement preparation reporting management assessed effectiveness abbvie 's internal control financial reporting december making assessment management used criteria set forth committee sponsoring organizations treadway commission coso internal controlintegrated framework framework based assessment management concluded abbvie maintained effective internal control financial reporting december based coso criteria effectiveness abbvie 's internal control financial reporting december audited ernst young llp independent registered public accounting firm stated attestation report appearing hereof expresses unqualified opinion effectiveness abbvie 's internal control financial reporting december report independent registered public accounting firm board directors shareholders abbvie inc audited abbvie inc subsidiaries ' internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission framework coso criteria abbvie inc subsidiaries ' management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinion company 's internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion abbvie inc subsidiaries ' maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated balance sheet december related consolidated statements earnings comprehensive income equity cash flows years ended report dated february expressed unqualified opinion thereon ernst young llp chicago illinois february part iii item directors executive officers corporate governance incorporated herein reference information concerning director nominees board directors committeescommittees board directors section beneficial ownership reporting compliance procedure recommendation nomination directors transaction business annual meeting included abbvie inc proxy statement proxy statement filed march also incorporated herein reference text found caption executive officers registrant pages hereof abbvie 's code business conduct requires business activities conducted compliance laws regulations ethical principles values directors officers employees abbvie required read understand abide requirements code business conduct applicable abbvie 's code business conduct available corporate governance section abbvie 's investor relations website wwwabbvieinvestorcom waiver code business conduct directors executive officers may made abbvie 's audit committee abbvie disclose amendment waiver provision code conduct principal executive officer principal financial officer principal accounting officer controller persons performing similar functions website within four business days following date amendment waiver addition abbvie disclose waiver code business conduct executive officers directors website abbvie chief ethics compliance officer reports chief executive officer public policy committee chief ethics compliance officer responsible overseeing administering monitoring abbvie 's compliance program item executive compensation material included proxy statement headings director compensation executive compensation compensation committee report incorporated herein reference proxy statement filed march item security ownership certain beneficial owners management related stockholder matters equity compensation plan information following table presents information december abbvie 's equity compensation plans abbvie common stock authorized issuance c number securities remaining number b available securities weighted future issuance issued upon average exercise equity exercise price compensation outstanding outstanding plans excluding options options securities warrants warrants reflected plan category rights rights column equity compensation plans approved security holders equity compensation plans approved security holders total includes shares issuable abbvie 's incentive stock program pursuant awards granted abbott adjusted abbvie awards connection abbvie 's separation abbott weightedaverage exercise price include outstanding restricted stock units restricted stock awards exercise price b information concerning security ownership incorporated herein reference material heading securities ownershipsecurities ownership executive officers directors proxy statement proxy statement filed march item certain relationships related transactions director independence material included proxy statement headings board directors committees corporate governance materials procedures approval related person transactions incorporated herein reference proxy statement filed march item principal accounting fees services material included proxy statement headings audit fees nonaudit fees policy audit committee preapproval audit permissible nonaudit services independent registered public accounting firm incorporated herein reference proxy statement filed march part iv item